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ABSTRACT 
 Despite the availability of well-established psychosocial and pharmacological treatments 
for attention-deficit/hyperactivity disorder (ADHD), it remains a disorder with substantial impact 
on public health and individual families.  Though the rate of adherence to ADHD medication is 
similar to that of other pediatric chronic conditions, research with this population is more limited.  
The current study explored the hypothesis that recognition by caregivers of child functional 
impairment, and caregiver perception of the doctor’s medication recommendation as “hasty” 
would account for statistically significant variance in adherence to ADHD medication.  Fourteen 
caregivers of children between the ages of 6 and 12 years diagnosed with ADHD and prescribed 
an index medication within 6 months of recruitment participated in the current study.  Measures 
included medication recommendation visual analog scale, Southampton ADHD Medication 
Behaviour and Attitudes Scale, Stimulant Adherence Measure, Vanderbilt ADHD Diagnostic 
Parent Rating Scale, and pharmacy data (i.e., medication possession ratios [MPR]).  We found 
significant correlations between adherence (i.e., MPR) and the following: number of days 
included in the MPR, τ = – .41, p (one-tailed) = .05, percent of children at Title 1 school 
considered low-income, τ = – .50, p (two-tailed) = .07, and highest grade-level completed by 
participant being greater than high school, τ = – .41, p (two-tailed) = .10.  While the hypothesis 
was not supported, the relationships were in the hypothesized direction and warrant further 
investigation with a larger sample size.  Clinicians who wish to improve adherence to ADHD 
medication in children may do so by working toward improving interactions between physician 
and caregivers (e.g., increasing shared decision-making between physician and caregivers).  
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Attention-Deficit/Hyperactivity Disorder (ADHD): Diagnosis and Features 
 As the most common neurobehavioral disorder in childhood, ADHD is estimated to 
affect approximately eight percent of children in the United States (US; Merikangas et al., 2010; 
Pastor & Reuben, 2008; Visser, Lesesne, Perou, & Blumberg, 2007).  Recent estimates indicate 
that a significant (i.e., 21.8%) increase in parent-reported ADHD occurred in the US between 
2003 and 2007 (Visser, Bitsko, Danielson, Perou, & Blumberg, 2010).  More than five million 
children in the US are estimated to have ADHD (Bloom, Cohen, & Freeman, 2010; Visser et al., 
2010).  Every classroom in the US is likely to have at least one student with ADHD (Hoza, 2007; 
Millichap, 2010).  Likewise, ADHD is a common referral concern in primary care settings 
(American Academy of Pediatrics [AAP], 2011). 
 ADHD is characterized by pervasive (i.e., not episodic) developmentally inappropriate 
symptoms of hyperactivity-impulsivity (HI) and/or inattention (American Psychiatric 
Association [APA], 2000).  According to the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV) the following criteria must be met in order to receive a diagnosis of ADHD: 
(a) symptoms of HI and/or inattention with associated impairment are present prior to seven 
years of age; (b) these symptoms cause impairment in at least two settings (e.g., school, home); 
(c) clinically significant impairment is present in social, academic, or occupational functioning; 
and (d) the symptoms do not occur exclusively during the course of a Pervasive Developmental 
Disorder (PDD), Schizophrenia, or other Psychotic Disorder, and are not better accounted for by 
another mental disorder (APA, 2000).  The DSM-IV recognizes three ADHD subtypes: (a) 
Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type (ADHD-I; 314.00) – 
assigned when six (or more) symptoms of inattention are present for at least six months with 
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fewer than six symptoms of HI; (b) Attention-Deficit/Hyperactivity Disorder, Predominantly 
Hyperactive-Impulsive Type (ADHD-HI; 314.01) – assigned when six (or more) symptoms of 
HI are present for at least six months with fewer than six symptoms of inattention; and (c) 
Attention-Deficit/Hyperactivity Disorder, Combined Type (ADHD-C; 314.01) – assigned when 
six or more symptoms of both inattention and HI are present for at least six months (see Table 1 
for list of symptoms).  ADHD-C is the most commonly diagnosed subtype with 50 to 60% of 
children with this presentation, followed by 30 to 40% with ADHD-I, and approximately 10% 
with ADHD-HI (AAP and National Initiative for Children’s Healthcare Quality [NICHQ], 
2002).   
Table 1.  Diagnostic and Statistical Manual (DSM-IV) Criteria for Attention-
Deficit/Hyperactivity Disorder (ADHD) 
A. Either (1) or (2): 
(1) six (or more) of the following symptoms of inattention have persisted for at least 6 
months to a degree that is maladaptive and inconsistent with developmental level: 
 
Inattention 
(a) often fails to give close attention to details or makes careless mistakes in schoolwork, 
work, or other activities 
(b) often has difficulty sustaining attention in tasks or play activities 
(c) often does not seem to listen when spoken to directly 
(d) often does not follow through on instructions and fails to finish school work, chores, 
or duties in the workplace (not due to oppositional behavior or failure to understand 
instructions) 
(e) often has difficulty organizing tasks and activities 
(f) often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental 
effort (such as schoolwork or homework) 
(g) often loses things necessary for tasks or activities (e.g., toys, school assignments, 
pencils, books, or tools) 
(h) is often easily distracted by extraneous stimuli 
(i)  is often forgetful in daily activities 
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Table 1 Continued.  Diagnostic and Statistical Manual (DSM-IV) Criteria for Attention-
Deficit/Hyperactivity Disorder (ADHD) 
(2) six (or more) of the following symptoms of hyperactivity-impulsivity have persisted for 




(a) often fidgets with hands or feet or squirms in seat   
(b) often leaves seat in classroom or in other situations in which remaining seated is 
expected 
(c) often runs about or climbs excessively in situations in which it is inappropriate (in 
adolescents or adults, may be limited to subjective feelings of restlessness) 
(d) often has difficulty playing or engaging in leisure activities quietly 
(e) is often "on the go" or often acts as if "driven by a motor" 
(f) often talks excessively 
 
  Impulsivity 
(g) often blurts out answers before questions have been completed 
(h) often has difficulty awaiting turn 
(i) often interrupts or intrudes on others (e.g., butts into conversations or games) 
 
B. Some hyperactive-impulsive or inattentive symptoms that caused impairment were present 
before age 7 years. 
 
C. Some impairment from the symptoms is present in two or more settings (e.g., at school [or 
work] and at home). 
 
D. There must be clear evidence of clinically significant impairment in social, academic, or 
occupational functioning. 
 
E. The symptoms do not occur exclusively during the course of a Pervasive Developmental 
Disorder, Schizophrenia, or other Psychotic Disorder and are not better accounted for by another 
mental disorder (e.g., Mood Disorder, Anxiety Disorder, Dissociative Disorder, or a Personality 
Disorder). 
 
Gender.  Male-to-female ratios range from 2:1 to 9:1 (APA, 2000).  High ratios are 
reported when based on clinical as opposed to community samples (APA, 2000).  Girls are more 
likely than boys to have ADHD-I (Biederman et al., 2002).  Boys with ADHD are more likely 
than girls with ADHD to exhibit rule-breaking and externalizing behavior problems (Abikoff et 
al., 2002).  A study utilizing structural equation modeling further examined this association and 
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concluded the pathway between gender and rule-breaking is mediated by HI symptoms 
(Vitulano, Fite, Wimsatt, Rathert, & Hatmaker, 2012).  
When study recruitment is not contingent on clinic referral, but rather occurs in the 
community, data indicate there are no differences in clinical correlates (e.g., psychosocial 
functioning) between boys and girls with ADHD (Biederman et al., 2005).  Explanations for this 
finding vary.  Some suggest clinicians’ inappropriate use of heuristics may contribute to over-
diagnosis of ADHD in boys (Bruchmüller, Margraf, & Schneider, 2012).  Teacher ratings of 
boys and girls with ADHD indicate teachers tend to rate boys as more impaired than girls 
(Gershon, 2002).  Disruptive behavior is likely recognized upon school entry.  However, 
clinically significant inattention, which is more common in girls, may not be recognized until 
late childhood (APA, 2000; Millichap, 2010).  Overall, symptoms of inattention are less likely to 
elicit a referral for services than are disruptive behaviors related to symptoms of HI (Biederman 
et al., 2005; Gershon, 2002).  Thus, the evidence regarding the role of gender on symptoms and 
outcomes in ADHD is equivocal and likely biased by referral practices. 
ICD-10.  Prevalence of ADHD using DSM-IV criteria is expected to be higher than with 
the ICD-10 for several reasons (Polanczyk, Silva de Lima, Horta, Biederman, & Rohde, 2007).  
First, the ICD-10 requires a minimum number of symptoms from each of three dimensions 
(inattention, overactivity, and impulsivity) be present for a diagnosis (World Health Organization 
[WHO], 1993).  The DSM-IV classifies HI symptoms together to form one dimension and 
permits a diagnosis with a minimum number of symptoms present in only one dimension.  
Second, the ICD-10 requires all diagnostic criteria be met in two or more different contexts (e.g., 
home and school).  The DSM-IV is less stringent requiring only some degree of impairment be 
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present in two or more settings.  Third, the ICD-10 identifies mood, anxiety, and developmental 
disorders as exclusions.  The DSM-IV allows mood and anxiety to be comorbid with ADHD. 
Comorbidity.  Several disorders are commonly comorbid with ADHD.  In fact, it is 
more likely than not that a child with ADHD will have a second psychiatric diagnosis 
(Ollendick, Jarrett, Grills-Taquechel, Hovey, & Wolff, 2008).  Using DSM-IV criteria, 
approximately 50% of children referred for ADHD also have oppositional defiant disorder 
(ODD) or conduct disorder (CD) (APA, 2000).  In general, ADHD and comorbid CD is 
associated with poorer outcomes relative to children without CD (Biederman, Newcorn, & 
Sprich, 1991).   
Comorbid mood disorders are also associated with greater impairment in psychosocial 
functioning and possibly greater risk for suicidality than in children with ADHD and no mood 
disorder (Biederman et al., 1992; Biederman et al., 1991).  Meta-analysis and longitudinal 
studies indicate that youth with ADHD have increased risk for major depression (Angold & 
Costello, 1993; Biederman et al., 1992; Biederman et al., 2008; Chronis-Tuscan et al., 2010).  
Initial studies indicate that adverse life events dependent on the child’s behavior (e.g., poor 
grades, interpersonal conflict) occur more frequently in youth with ADHD and should be a target 
of intervention to address risk of comorbid major depression (Daviss & Diler, 2012). 
Approximately 25% of children with ADHD are also diagnosed with an anxiety disorder 
(Biederman et al., 1992; Biederman et al., 1991).  This figure may underestimate the prevalence 
of ADHD and comorbid anxiety disorders because anxiety is often overlooked in hyperactive 
children (Spencer, Biederman, & Mick, 2007).  Findings of a longitudinal study indicate children 
with ADHD and a comorbid anxiety disorder experience greater psychosocial impairment, 
psychiatric treatment, and family history of anxiety disorders (Biederman et al., 1996).  
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 Approximately 60% of individuals who are referred for Tourette’s Disorder (TD) also 
have ADHD (Biederman et al., 1991; Freeman et al., 2000).  Most people with ADHD do not 
have TD.  However, when these disorders are comorbid, ADHD onset tends to precede TD 
(APA, 2000).  Data indicate tic disorders and ADHD are distinct disorders with different 
presentations over time; ADHD is less likely to remit over time (Biederman et al., 1996; Spencer 
et al., 1999).  Initial evidence suggesting stimulant medication may exacerbate tics led to limited 
use of this medication class to treat ADHD (Wigal, 2009).  More recent evidence indicates the 
impairment associated with untreated ADHD supercedes that of tic disorders and use of 
stimulant medications for children with ADHD and comorbid TD is no longer contraindicated 
(Pringsheim & Steeves, 2011).  Furthermore, evidence of the efficacy of alternative 
pharmacotherapy interventions suggest greater benefits relative to costs of treating ADHD in 
individuals with comorbid tic disorders (Allen et al., 2005; Pringsheim & Steeves, 2011; 
Tourette Syndrome Study Group, 2002)  
 Revisions for DSM-5.  Based on available evidence, the ADHD and Disruptive Behavior 
Disorders Workgroup of APA made several revisions for ADHD in DSM-5 (APA, 2013).  First, 
ADHD is included in the new diagnostic category of Neurodevelopmental Disorders.  Second, 
there is a change in the requirement for the onset of impairing symptoms by age seven to onset of 
symptoms (i.e., presence, not necessarily impairment) by age 12.  This recommendation is based 
on a systematic literature review that concluded altering the onset criterion would maintain 
ADHD as having childhood onset, while reducing the number of false negatives (i.e., individuals 
with ADHD who do not meet criteria by age seven) (Keiling et al., 2010).  Third, the three 
subtypes described previously are three current presentations.  This recommendation addresses 
concerns regarding the validity of the DSM-IV subtypes and is based on a literature review and 
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meta-analysis conducted by Willcut and colleagues (2012).  The authors conclude that available 
longitudinal data do not support the current use of ADHD subtypes as representing distinct 
groups of individuals with stable differences.  Fourth, DSM-5 includes examples of inattentive 
and HI symptoms that are relevant to individuals with ADHD across the lifespan.  Fifth, PDD is 
removed from the exclusion criteria.  This recommendation is based on evidence that ADHD 
symptoms are commonly present in individuals with PDD (Coghill & Seth, 2011; Frazier et al., 
2001; Goldstein & Schwebach, 2004; Simonoff et al., 2008).  Thus, both diagnoses must be 
made accurately in order to receive effective treatment for each.  Sixth, the recommendation that 
data be obtained from multiple informants (e.g., parent, teacher) is emphasized.  This is currently 
identified in best-practice guidelines for assessment of ADHD, but may be overlooked by 
clinicians (Coghill & Seth, 2011; Valo & Tannock, 2010).  Seventh, DSM-5 includes a specifier 
for current severity: mild, moderate, or severe. 
Negative Consequences of ADHD 
 Childhood ADHD has an array of negative consequences such as impaired academic and 
peer functioning, decreased quality of life (QOL), increased likelihood of engaging in risky 
behaviors, and high economic burden.  Impaired functioning often persists into adulthood (Klein 
et al., 2012).  While long-term outcomes in those who receive ADHD treatment are favorable to 
those who do not, they do not reach levels of individuals without ADHD (Shaw et al., 2012). 
 Academic functioning.  Overall, ADHD is associated with impairment in academic 
functioning.  Studies find that children with ADHD score significantly lower on standardized 
tests of reading/language, mathematics, and written language relative to controls (Barbaresi et 
al., 2006; Massetti et al., 2008; McConaughy, Volpe, Antshel, Gordon, & Eiraldi, 2011).  
Frazier, Youngstrom, Glutting, & Watkins (2007) conducted a meta-analysis of 72 studies 
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published from 1990 to 2005 examining academic underachievement associated with ADHD.  
Results indicated a medium effect of ADHD on overall levels of achievement (d = .71, z = 12.28, 
p = .001).  Effect sizes for individual content areas (i.e., reading, mathematics, and spelling) were 
also statistically significant and of medium size.  Results of longitudinal studies indicate these 
poor academic outcomes persist into adolescence and young adulthood (Loe & Feldman, 2007).  
Additional differences between children with ADHD and controls include higher likelihood of 
receiving special education, retaining a grade, being suspended or expelled, and dropping out 
before high school graduation (Barbaresi et al., 2006; Jensen et al., 2004; LeFever, Villers, 
Morrow, & Vaughn, 2002).   
Peer functioning.  In a review of the literature on peer relationships of children with 
ADHD, Hoza (2007) emphasized the impact of core symptoms of ADHD (i.e., HI and 
inattention) in developing and maintaining detrimental relationships with peers.  Research 
involving clinical samples of children with ADHD is limited (Hoza, 2007).  However, the 
literature consistently supports the following: (a) both boys and girls with ADHD demonstrate 
impairment in peer functioning; (b) a peer-initiated label of “ADHD” is associated with peer 
rejection; and (c) it is difficult to ameliorate the problematic peer relationships of children with 
ADHD (Hoza, 2007; Murray-Close et al., 2010; Nijmeijer et al., 2008).   
 Difficulties in peer functioning for children with ADHD are often discussed in terms of 
inappropriate levels of negative behavior and deficits in performance and skills (Wheeler & 
Carlson, 1994).  A longitudinal study conducted by Bagwell, Molina, Pelham, & Hoza (2001) 
followed 111 children with and 100 children without ADHD for five years into adolescence.  
According to parent report, children with ADHD had greater peer rejection and fewer close 
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friendships relative to the non-ADHD group.  Effects of ADHD on peer functioning were 
marked in participants with ADHD or CD in adolescence.   
Hoza and colleagues (2005) conducted a study using peer sociometric methods to 
evaluate the peer relationships of 165 children with ADHD enrolled in the Multimodal 
Treatment of ADHD (MTA) study, and randomly selected non-ADHD comparison children 
matched by sex and classroom.  After controlling for comorbid ODD/CD and anxiety, results 
indicated MTA children had significantly impaired peer relationships compared to children 
without ADHD on several indicators (e.g., fewer dyadic friendships, lower social preference).  
Of note, children with ADHD demonstrated poor peer functioning regardless of MTA treatment 
group assignment and despite improvement in other domains such as ADHD symptoms.  This 
result is not surprising in light of evidence that the efficacy of interventions for peer problems of 
children with ADHD is limited (Mrug, Hoza, & Gerdes, 2001). 
QOL.  The WHO describes QOL as “the individuals perception of their position in life, 
in the context of culture and value systems in which they live, and in relation to their goals, 
expectations, standards and concerns” (WHOQOL Group; 1995, p. 1405).  In contrast to health 
status and functional impairment, QOL is subjective and essentially a patient-reported outcome 
(Coghill, Danckaerts, Sonuga-Barke, Sergeant, & The ADHD European Guidelines Group, 
2009).  While several generic QOL measures exist, three have been rigorously studied in child 
and adolescent mental health (Coghill et al., 2009): (a) Child Health Questionnaire (CHQ; 
Landgraf, Abetz, & Ware, 1999); (b) Pediatric Quality of Life Inventory (PedsQL; Varni, Seid, 
& Kurtin, 2001); and (c) Child Health and Illness Profile (CHIP; Riley et al., 2004a, 2004b).  
Two measures specific to ADHD may prove useful in treatment outcome, but are currently in 
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initial phases of development: (a) Weiss Functional Impairment Scale (Weiss & Brooks, 2007); 
and (b) ADHD Impact Module (Landgraf, Rich, & Rappoport, 2002). 
 Danckaerts et al. (2010) conducted a systematic review of 36 QOL studies in youth with 
ADHD.  Results suggested the overall impact of ADHD on QOL is commensurate with that of 
chronic physical illnesses as well as other mental health conditions.  The most substantial 
negative impact appeared to be in psychosocial domains, particularly achievement and family 
functioning.   
  Despite recognition that patient self-report is essential when evaluating QOL (Coghill et 
al., 2009; Matza, Swensen, Flood, Secnik, & Leidy, 2004), the authors reported only seven of 36 
studies included patient self-report ratings.  Agreement between children and their parents was 
greater for physical (rs = 0.60 to 0.75) than psychosocial subscales (rs = 0.40 to 0.48).  In 
general, children rated their own QOL higher than their parents and may not view their QOL as 
impaired in comparison to healthy controls.  The authors cited the positive illusory bias as a 
possible influence for this result.  The positive illusory bias suggests individuals overestimate 
their abilities across domains (e.g., academic, social) in spite of established functional 
impairment (Owens, Goldfine, Evanelista, Hoza, & Kaiser, 2007).  
 Overall, Danckaerts and colleagues (2010) reported a significant negative correlation 
between QOL and ADHD symptoms.  Thus, evidence suggested these constructs are connected, 
but discrete and both are required for a comprehensive understanding of a child’s functioning.  
The authors further discussed the evidence that QOL improves following treatment.  However, 
they emphasized that the majority of studies have examined only the medication atomoxetine 
(Strattera) and rely on parent-proxy report. 
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 Coghill (2010) conducted a systematic review specifically investigating the effect of 
medications on QOL in ADHD.  The author concluded that children with ADHD generally 
report QOL one-and-a-half to two standard deviations below population norms, which is similar 
to children with chronic physical illnesses.  He further observes that side effects associated with 
ADHD medications (e.g., stomach pain, headache) are likely to negatively impact QOL 
particularly in the physical health domain.  While available studies are limited, the current 
literature supports a favorable short-term impact of medication on QOL in ADHD.  This effect is 
similar to that of medication on ADHD symptoms, but with smaller effect sizes.   
High-risk behavior.  Studies suggest that ADHD is associated with increased 
delinquency, alcohol and substance use or abuse, risky sexual behaviors, and unsafe driving.  
Molina and colleagues (2007a) reported that MTA children engaged in significantly higher rates 
of delinquency compared to a local normative comparison group at 36 months after MTA 
randomization (27.1% vs. 7.4%; p < .001).  While studies are generally consistent in the finding 
that childhood ADHD increases the likelihood of delinquent behavior in adolescence or 
adulthood, it is unclear whether this is a direct effect of ADHD or its association with other 
common comorbid disruptive behavior disorders (e.g., ODD, CD) (von Polier, Vloet, & 
Herpertz-Dahlmann, 2012).  Findings from the Pittsburgh ADHD Longitudinal Study (PALS) 
suggested that irrespective of comorbidity, all children with ADHD are at higher-risk for 
engaging in delinquent behavior (Sibley et al., 2011).  Nevertheless, boys with ADHD and 
comorbid CD were at greatest risk of delinquency.  In contrast, Satterfield and colleagues (2007) 
reported that boys diagnosed with hyperactivity, but not conduct problems, did not demonstrate 
increased risk for engaging in criminal behavior in adulthood.  
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 Molina, Pelham, Gnagy, Thompson, & Marshal (2007b) also reported MTA children had 
significantly higher rates of substance use compared to a local normative comparison group.  
Similarly, a second study involving adolescents or young adults from PALS found elevated 
indicators of alcohol use among some (i.e., 15 to 17-year-olds), but not all, age groups with 
ADHD (Molina et al., 2007b).  Charach, Yeung, Climans, & Lillie (2011) conducted a meta-
analysis of 13 prospective cohort studies.  Findings indicated that childhood ADHD significantly 
increases the risk of nicotine use in adolescence, and alcohol use disorders in young adulthood.  
The independent contribution of childhood ADHD (i.e., without comorbid disorders) to 
increased risk of substance use disorders later in life is equivocal (e.g., Brook, Brook, Zhang, & 
Koppel, 2010; Wilens et al., 2011).  
 Initial evidence suggests childhood ADHD is associated with various indicators of risky 
sexual behavior in young adulthood.  As part of PALS, self-reported risky sexual behaviors of 
men ages 18 to 26 years (n = 175) with childhood ADHD were compared to that of men with 
similar demographics and no ADHD (n = 111) (Flory, Molina, Pelham, Gnagy, & Smith, 2006).  
Men with childhood ADHD reported more sexual partners, casual sex, and partner pregnancies, 
and younger age of initiation of sexual activity and intercourse.  This finding remained after 
accounting for childhood conduct problems.  
 In a second study including participants from PALS, adolescents and young adults with 
childhood ADHD (n = 203) and controls (n = 152) completed the Young Adult Driving 
Questionnaire (Thompson, Molina, Pelham, & Gnagy, 2007).  Findings indicated that presence 
of childhood ADHD is associated with increased risky driving in adolescence and young 
adulthood.  Specifically, participants with ADHD had significantly higher number of accidents 
and tickets in the last six months as well as number of lifetime tickets.  Adolescents and young 
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adults with childhood ADHD were more likely than controls to ever have driven without a 
license.  HI at follow-up was found to be a significant mediator of tickets and accidents.  In light 
of risky driving behavior by adolescents with ADHD, the AAP recommends physicians take care 
to prescribe ADHD medication that remains active during prime driving hours (AAP, 2011).  
 Economic burden.  Overall, childhood ADHD is associated with substantial economic 
burden and subsequent public health importance (Pelham, Foster, & Robb, 2007).  Based on a 
small number of published studies, Pelham et al. (2007) estimated the annual cost of illness 
(COI) of ADHD to be $14,576 per child.  The authors noted that using a conservative prevalence 
of 5%, the overall COI of ADHD would be $42.5 billion for school-aged children in the US.  
ADHD is a unique chronic condition in that its COI is shared by individual families, as well as 
the education and health care systems (Pelham et al., 2007).  To date, no studies detailing the 
cost of ADHD to families (e.g., loss of parent work productivity) have been published.   
Based on data from PALS, Robb et al. (2011) reported the annual cost of educating a 
student with ADHD to be significantly higher than students in the comparison group ($5,007 
versus $318).  Pelham et al. (2007) estimated costs associated with crime and delinquency in 
ADHD to be $7040 per year.  The authors did not identify any studies reporting the costs 
associated with alcohol or drug abuse in ADHD.  Considering the costs for pharmacological and 
psychosocial mental health treatment for ADHD as well as costs associated with other health 
services for children with ADHD, yearly cost to the health care system for one child is estimated 
to be $2636 (Pelham et al., 2007).  Costs associated with children with ADHD and comorbid 
disorders are likely greater than that of ADHD alone (Jones, Foster, & Conduct Problems 
Prevention Research Group, 2009). 
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ADHD: Assessment and Treatment 
 Evidence-based assessment (EBA) of ADHD.  The etiology of ADHD remains largely 
unknown (APA, 2000).  No medical test exists to accurately and reliably diagnose ADHD (APA, 
2000).  As such, use of EBA of ADHD is paramount (Pelham, Fabiano, & Massetti, 2005).  A 
primary goal of EBA of ADHD is to determine whether a child’s behavior sufficiently deviates 
from typical or developmentally appropriate behavior as to warrant a diagnosis (Pelham et al., 
2005).  This requires data based on behavioral observations made by parents and teachers (AAP, 
2011).  Pelham and colleagues (2005) described parent and teacher rating scales as the “sine qua 
non” for diagnosing ADHD (p. 462).  This endorsement is consistent with practice parameters 
from The American Academy of Child and Adolescent Psychiatry (AACAP).  The AACAP has 
established guidelines for the assessment of ADHD in children and adolescents (AACAP Work 
Group on Quality Issues, 2007). 
Among recommendations outlined by the AACAP is the use of both broadband and 
narrowband rating scales to screen and assess for symptoms of ADHD and associated level of 
impairment.  Commonly used broadband measures with good reliability and validity include the 
Child Behavior Checklist (CBCL, Achenbach & Rescorla, 2001) and Behavior Assessment 
System for Children, Second Edition (BASC-2, Reynolds & Kamphaus, 2004).  Narrowband 
rating scales are based on the DSM-IV criteria for ADHD.  Commonly used narrowband 
measures with good reliability and validity include the ADHD Rating Scale-IV Home and 
School Versions (Dupaul, Power, Anastopoulos, & Reid, 1998) and the Vanderbilt ADHD 
Diagnostic Parent and Teacher Scales (Wolraich, Lambert, Bickman, Simmons, Doffing, & 
Worley, 2004). 
A clear description and understanding of the strengths and limitations of specific ADHD 
rating scales is useful when selecting a measure (see Collett, Ohan, & Myers, 2003 for a 
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comprehensive review).  EBA of ADHD further necessitates careful inquiry of psychosocial 
impairment commonly present in children with ADHD – family functioning, peer relationships, 
and academic functioning (Fabiano et al., 2006; Pelham et al., 2005).   
 Evidence-based treatment of ADHD.  Pharmacological intervention for ADHD has 
long been established as efficacious (Pelham, Wheeler, & Chronis, 1998).  FDA-approved 
medications for the treatment of childhood ADHD include various central nervous system (CNS) 
stimulants, and one selective norepinephrine reuptake inhibitor (National Institute of Mental 
Health [NIMH], 2010).  The MTA study directly evaluated the efficacy of four treatment modes: 
(a) medication management only; (b) behavioral intervention only; (c) a combination of both; 
and (d) routine community care.  The MTA was a large multisite study including 579 children 
ages seven to nine years diagnosed with ADHD.  Primary results were reported including a 14-
month follow-up (MTA Cooperative Group, 1999).  
 Combination treatment and medication management alone both resulted in significantly 
fewer ADHD symptoms at 14-month follow-up than behavioral treatment alone or routine 
community care.  Children who received combination treatment exhibited superior functioning 
(e.g., academic performance, social skills) than those assigned to other intervention conditions.  
Likewise, children in the combined treatment condition had lower doses of medication than those 
in the medication management alone condition.  This finding is important because side effects 
from stimulant medications (e.g., sleep problems, loss of appetite) are dose-dependent (NIMH, 
2010). 
 These findings suggest a combination of pharmacological and behavioral interventions 
are indicated for an evidence-based approach to treatment for ADHD. Pelham & Fabiano (2008) 
conducted a review of ADHD intervention studies published between January 1997 and 
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September 2006 (see Pelham et al., 1998 for a review of studies published prior to 1997).  
Behavioral parent training, behavioral classroom management, and behavioral interventions 
implemented in peer group/recreational settings are classified as well-established interventions 
according to criteria designated by the Task Force on Promotion and Dissemination of 
Psychological Procedures (1995). 
Behavioral parent training often takes place in a group setting over eight to 16 sessions.  
Characteristics common to behavioral parent training include: (a) psychoeducation about ADHD; 
(b) strategies for attending to and increasing appropriate child behaviors as well as consequences 
for problematic behaviors; and (c) methods to provide structure to the home environment as well 
as establish clear expectations (Barkley, 1997; Hoza, Kaiser, & Hurt, 2007; McMahon & 
Forehand, 2003).  Skills of effective behavioral classroom management are similar to those of 
behavioral parent training with teachers in the classroom setting.   
Daily Report Cards (DRCs) are an important addition to a behavioral classroom 
management intervention.  Use of a DRC intervention involves teachers evaluating children on 
identified target behaviors in the school setting (e.g., talking without permission) and providing 
daily feedback to parents.  Parents then enact contingencies at home based on the child’s 
performance in school.  Parents learn to establish reasonable goals, and to develop and maintain 
a home-based reward system (AAP & NICHQ, 2002).  DRCs have substantial efficacy (Pelham 
& Fabiano, 2008).   
Behavioral interventions implemented in peer group/recreational settings often include 
summer treatment programs (STPs).  The Pelham STP is an intensive summer day program that 
provides behavioral intervention using a point system with reward and response-cost 
components, sport skills training, academic programs, and social skills training (Pelham & Hoza, 
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1996).  Traditional social-skills groups conducted weekly (i.e., not an intensive summer day 
program) are not an evidence-based intervention for ADHD (Pelham & Fabiano, 2008).  
Likewise, Pelham & Fabiano (2008) found no support for the use of nonbehavioral 
psychotherapeutic interventions or cognitive-behavioral therapy for treatment of ADHD. 
 Given the high prevalence of ADHD and the corresponding number of children that seek 
treatment in various settings, a number of professional organizations have established clinical 
practice guidelines to assist members in providing evidence-based treatment.  The American 
Medical Association (AMA) guideline emphasizes that treatment for ADHD generally includes 
pharmacotherapy and adjunctive behavioral interventions with occasional supportive 
psychotherapy with the child and/or family (Goldman, Genel, Bezman, & Slanetz, 1998).  The 
AAP established recommendations based on age of the child (AAP, 2011).  The first line of 
treatment for preschool-aged children (i.e., four to five years) is evidence-based behavior therapy 
administered by parents and/or teachers.  If the child continues to experience moderate-to-severe 
disturbances in functioning, the clinician may consider prescribing methylphenidate.  Preferable 
intervention for elementary school-aged children (i.e., six to 11 years) is FDA-approved 
medications for ADHD and evidence-based behavior therapy administered by parent and/or 
teacher.  Intervention recommendations for adolescents are similar with additional emphasis on 
obtaining the adolescent’s assent to medication.  An APA task force (2006) concluded the 
evidence-base for CNS stimulants, behavioral interventions, and the combination of the two is 
unequivocal in the short-term.  However, current data did not support long-term use (i.e., greater 
than two to three years) of CNS stimulants. 
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Treatment Adherence: Definitions and Considerations 
The WHO defines adherence as “the extent to which a person’s behavior – taking 
medication, following a diet, and/or executing lifestyle changes – corresponds with agreed 
recommendations from a health care provider” (2003, p. 16).  This definition highlights several 
important characteristics of adherence.  First, adherence is not dichotomous (e.g., good or bad, 
adherent or nonadherent), and should be assessed using continuous measures (DiMatteo, 
Giordani, Lepper, & Croghan, 2002; Dirks & Kinsman, 1982; La Greca, 1990; Rapoff, 2010; 
Rudd et al., 1989).  Second, adherence must be explicitly defined based on specific behaviors as 
prescribed for a particular regimen (Rand & Wise, 1994; Rudd, 1993).  Third, adherence 
measures agreement between a patient’s prescribed behavior and actual behavior (Rapoff, 2010).  
This may take several forms (Farmer, 1999; Dunbar-Jacob & Schlenk, 2001; Horne, 2006).  
Fourth, consistent with a patient-centered approach to adherence, patients are encouraged to 
participate in the decision-making process to determine an agreed upon treatment regimen 
(Adams, Dreyer, Dinakar, & Portnoy, 2004). 
Some investigators differentiate between unintentional and volitional nonadherence 
(Adams et al., 2004; Bauman, 2000; Graves, Adams, Bender, Simon, & Portnoy, 2007).  The 
proposed distinction is that volitional nonadherence represents a rational decision or choice not 
to comply with provider recommendations (Bauman, 2000).  Volitional or intentional 
nonadherence has been defined as actively reducing, missing, or changing medication doses to 
be more consistent with the needs identified by the patient and/or patient’s family (Wroe, 2002).  
This definition emphasizes that from a patient-centered perspective, as opposed to physician as 
expert (Charles, Gafni, & Whelan, 1997; Charles, Gafni, & Whelan, 1999), volitional 
nonadherence may be adaptive (Deaton, 1985).  While the distinction between volitional and 
nonvolitional nonadherence is an interesting one, it has proven difficult to study because it is 
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unclear how to accurately determine a person’s intention in following or not following a 
particular medical regimen (Rapoff, 2010).  
Standard criteria for determining adherence versus nonadherence are yet to be 
established.  The convention in the field has been to consider participants/patients who take 80% 
or more of their prescribed medications to be “adherent” (Rapoff, 2010).  This cutoff is based on 
data from an adherence-promotion intervention that adult participants who took at least 80% of 
their hypertension medications experienced a decrease in blood pressure (Haynes et al., 1976).  
While this finding has implications for hypertension, its applicability to other diseases is 
questionable (Rapoff, 2010).  Treatment threshold effects – the amount of adherence necessary 
to achieve a positive effect of medical treatment – are rarely studied (Rapoff, 2010).  As such, 
the treatment threshold effect for most chronic medical and mental illnesses remains unknown 
(Epstein & Cluss, 1982; Rapoff, 2010).  This is true for ADHD even though initial evidence 
suggests possession of a stimulant medication on at least 70% of days in an academic marking 
period is associated with a statistically significant, but not clinically meaningful, improvement in 
grade point average (Marcus & Durkin, 2011). 
Poor adherence is a prevalent and clinically significant concern (Matsui, 2000).  Health 
professionals are in need of valid and reliable measures of their patients’ adherence to treatment 
regimens (Hughes, 2007; Modi et al., 2006).  While methods for assessing adherence are 
developing, there is currently no consensus in the literature regarding whether a gold standard of 
assessment exists (Cramer, 1995; Quittner, Modi, Lemanek, Ievers-Landis, & Rapoff, 2008; 
Rapoff, 2010; WHO, 2003).  Current methods of assessment include drug assays, observation, 
electronic monitors, pill counts, provider estimates, and patient/parental reports.  Each method 
possesses specific assets and liabilities that professionals should consider when selecting a 
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measure of adherence (see Quittner et al., 2008 and Rapoff, 2010 for detailed reviews).  The 
current recommendation is to include at least two methods of assessment and examine the 
convergence between the measures (Quittner et al., 2008). 
Adherence in Childhood ADHD 
 Research regarding medication adherence in childhood ADHD is limited.  What does 
exist is restricted by heterogeneous methodology (Chacko, Newcorn, Feirsen, & Uderman, 2010; 
Gajria et al., 2014).  Gajria and colleagues (2014) conducted a systematic review of 91 original 
studies and 36 expert opinion reviews published on the topic between 1990 and 2013.  Authors 
identified 25 studies reporting discontinuation or continuation/persistence rates focused on 
children and adolescents only.  However, only four studies reported data similar enough to 
calculate pooled results.  These studies generally defined persistence as number of days of 
continuous use of index (i.e., first or original) medication without a specified gap period of 30 
days.  Persistence results, reported as mean treatment duration, were 135.97 days for stimulant 
medications.  Short-acting medications had the shortest treatment duration of 92.99 days.  
Authors identified 12 studies reporting adherence results, defined as number of days of 
medication supplied during pre-specified period, for patients 18 years of age or younger.  
Quantitative results of pooled adherence data indicated mean medication possession ratios 
(MPR; ratio of number of days with mediation supply to total number of days in defined period) 
of 0.57 for stimulants in studies with 12-month follow-up and 0.49 in studies with 6-month 
follow-up.   
Chacko and colleagues (2010) also conducted a literature review of 17 empirical studies 
on ADHD medication adherence in youth.  These authors did not conduct any quantitative 
analyses, but reported a synthesis of the existing literature similar to Gajria and colleagues 
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(2014).  Results suggested consistent use of stimulant medication is evident in 1/3 to 2/3 of 
prescribed youth.  Studies also indicated that while short-term adherence varies considerably, 
long-term adherence is generally poor.  These rates and medication use patterns are similar to 
those reported in childhood chronic medical conditions (Rapoff, 2010).  A large number of 
families demonstrate almost immediate poor adherence to ADHD medications (Miller, Lalonde, 
McGrail, 2004).  In fact, approximately 20% never fill more than one prescription (Miller et al., 
2004). 
Gajria et al., (2014) also reported results of 31 original studies examining reasons for 
treatment discontinuation among children and adolescents.  The most frequently reported reasons 
were ineffectiveness/suboptimal response (21 studies), and adverse effects (21 studies).  Poor 
adherence was reported as a reason in seven studies.  Interestingly, the authors also reported 
results based on 24 expert opinion articles.  According to expert opinion, the most frequently 
reported reasons for treatment discontinuation among children and adolescents were adverse 
effects (15 studies), dosing inconvenience (10 studies), patient attitude (8 studies), and social 
stigma (8 studies).   
These reviews have highlighted the current state of the literature regarding medication 
adherence in childhood ADHD.  Most literature has solely focused on stimulant medications.  
Marginal improvement in adherence has been reported with extended-release medications 
(Faraone, Biederman, & Zimmerman, 2007; Marcus, Wan, Kemner, & Olfson, 2005).  Higher 
adherence rates have been reported in clinical research as opposed to community samples 




Caregiver Beliefs and Attitudes about ADHD 
 Data discussed above indicate the relatively high rates of medication nonadherence in 
childhood ADHD.  In addition to factors common to pediatric chronic illness conditions (Rapoff, 
2010), researchers postulate factors that uniquely influence medication adherence in childhood 
ADHD (Chacko et al., 2010; Hoza, Johnston, Pillow, & Ascough, 2006).  Many of these involve 
caregiver beliefs or attitudes about both assessment and treatment of ADHD.  This approach is 
reasonable given that caregivers are the “gatekeepers,” or ultimate decision-makers, concerning 
pediatric treatment (Hoza et al., 2006).  While much of this work is preliminary, relevant 
findings from qualitative and quantitative studies are discussed below. 
 Qualitative Studies.  Ahmed, McCaffery, & Aslani (2013) conducted a systematic 
review of qualitative studies examining considerations reported by caregivers who are deciding 
whether to initiate or continue stimulant medication for their child.  Authors searched five 
electronic databases for peer-reviewed, English-language studies published between January 
1980 and September 2011 with relevant MeSH terms and keywords.  Of 348 identified citations, 
11 met the following eligibility criteria: (a) used qualitative methods; (b) involved a treatment 
decision, made by caregiver(s) of a child, about use of stimulant medication; (c) child was 
officially diagnosed with ADHD; and (d) examined factors involved in the caregiver treatment 
decision-making process.    
 The 11 studies, mostly conducted in the United States (n = 6), included a total of 335 
participants.  The authors identified four major themes across studies: (a) confronting the 
diagnosis; (b) external influences; (c) apprehension regarding stimulant therapy; and (d) 
experiences with the healthcare system.   
Caregivers reported struggling to accept their child’s ADHD diagnosis, often exacerbated 
by trying to reconcile the image of children portrayed in the media with ADHD with the image 
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of their own child.  In addition to media portrayals, caregivers reported relying on an 
acquaintance that was a caregiver of a child with ADHD for information.  Many caregivers 
expressed hesitancy to accept ADHD as a legitimate condition.  Similarly, caregivers often cited 
short diagnostic evaluations as evidence against a biological etiology.  Several studies reported 
instances of one caregiver in agreement with ADHD diagnosis while the other was in complete 
opposition.  Interestingly, caregivers frequently accounted for their child’s behavior in other 
ways such as “boys will be boys” (Singh, 2003).   
 Caregivers identified several external sources of influence during the decision-making 
process.  They often cited media coverage focusing on sensationalized versions of ADHD-
related behaviors and treatment as troubling sources (Brinkman et al., 2009; Charach, Skyba, 
Cook, & Antle, 2006; dosReis, Barksdale, Sherman, Maloney, & Charach, 2010; dosReis, Zito, 
Safer, Soeken, Mitchell, & Ellwood, 2003; Jackson & Peters, 2008; Taylor, O’Donoghue, & 
Houghton, 2006).  Caregivers discussed how media coverage of “overprescribing” of ADHD 
medications, addictive properties of medications, and portrayals of children treated with 
medication as “zombie-like,” influenced their treatment decisions (Brinkman et al., 2009; 
dosReis et al., 2010).  They also discussed the contribution of media coverage to blaming 
caregivers as unwilling to or incapable of parenting their child because they choose to medicate 
their child (Charach et al., 2006; Taylor et al., 2006).  Caregivers reported that the views and 
opinions of others within their social networks and personnel from child’s school similarly 
influence their treatment decisions (Brinkman et al., 2009; Bussing & Gary, 2001; Charach et al., 
2006; Fiks, Hughes, Gafen, Guevara, Barg, 2011; Hansen & Hansen, 2006; Jackson & Peters, 
2008; Leslie, Plemmons, Monn, & Palinkas, 2007). 
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 In each of the 11 included studies, caregivers described concerns specific to stimulant 
medications.  They expressed concern about immediate side effects (e.g., growth stunting, liver 
damage, personality changes, appetite suppression) and long-term effects.  Caregivers also 
indicated fears of labeling and social isolation associated with child use of stimulant medications 
(Brinkman et al., 2009; Charach, et al., 2006; dosReis et al., 2010; Singh, 2003; Taylor et al., 
2006).  Some caregivers stated that financial burden of stimulant medications played a role in 
their treatment decisions (Fiks et al., 2011; Leslie et al., 2007). 
 All identified studies explored the influence of caregivers’ experiences with the 
healthcare system on treatment decisions.  Caregivers reported problematic interactions with 
healthcare providers characterized by perceived failure to effectively communicate and exchange 
information.  Caregivers explained that these interactions left them feeling marginalized and 
doubting healthcare providers’ recommendations, which exacerbated concerns of lax prescription 
practices (Brinkman et al., 2009; Bussing & Gary, 2001; Charach et al., 2006; dosReis et al., 
2003; Leslie et al., 2007; Taylor et al., 2006).   
 Quantitative Studies.  Given numerous caregiver misconceptions of ADHD (e.g., sugar 
and diet affect hyperactivity; dosReis et al., 2003), it seems intuitive that providing caregivers 
with accurate knowledge of ADHD would increase participation in evidence-based treatments 
for ADHD (Hoza et al., 2006).  Studies have demonstrated that increased ADHD knowledge is 
positively correlated with acceptability of and willingness to pursue evidence-based treatments 
(Bennet, Power, Rostain, & Carr, 1996; Liu, Robin, Brenner, & Eastman, 1991).  However, they 
have been limited by use of analog designs.  Evidence demonstrating actual treatment use 
differences over time is limited (Bennett et al., 1996; Corkum, Rimer, & Schachar, 1999).   
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Given the preliminary nature of research specifically targeting childhood ADHD, it is 
helpful to consider findings from similar, but more established literature such as adherence to 
pediatric medical regimens.  For example, educational adherence-promotion interventions (e.g., 
asthma, diabetes) have demonstrated a small effect size (Kahana, Drotar, & Frazier, 2008).  
Thus, educational strategies are typically combined with behavioral strategies, which have 
demonstrated a medium effect size (Graves, Roberts, Rapoff, & Boyer, 2010; Kahana, Drotar, & 
Frazier, 2008; Rapoff, 2010).  These findings suggest that increased knowledge or educational 
strategies are critical, but not adequate for treatment engagement or adherence (Quittner et al., 
2008; Rapoff, 2010). 
 Some researchers highlight parenting efficacy as a promising predictor of treatment 
initiation and adherence for ADHD; however, empirical support is limited (Hoza et al., 2006).  
Hoza and colleagues (2000) found, among other constructs, that low parenting efficacy in fathers 
was associated with poorer outcomes in a subsample of MTA participants.  This association 
maintained after controlling for MTA treatment effects.  Jiang and colleagues (2014) found a 
similar, but less robust association between parenting efficacy and ratings of treatment 
acceptability and effectiveness of behavioral parent training.  This study is also limited by an 
analog design with conclusions more relevant to “intentions” than actual behavior (e.g., 
Maniadaki, Sonuga-Barke, & Kakouros, 2006).  While self-efficacy is a useful and robust 
construct in predicting health-related behaviors, particularly in adults, evidence does not 
currently exist that it may be changed directly (Rapoff, 2010).  
 Caregiver Perception of Child Functional Impairment.  As discussed earlier, 
functional impairment is a key component of EBA for ADHD.  Functional impairment, not 
behavioral symptoms (e.g., inattention, hyperactivity), is most predictive of long-term outcome; 
  
 26 
symptom remission does not necessarily coincide with recovery of function (Harrison, Vannest, 
& Reynolds, 2011; Hinshaw et al., 2006; Mick, Faraone, & Biederman, 2004).  Children are 
typically referred for treatment based on functional problems in one or more domains commonly 
associated with impairment in children with ADHD: family functioning, peer relationships, and 
academic functioning (Angold, Costello, Farmer, Burns, & Erkanli, 1999; Evans & Youngstrom, 
2006; Pelham, Fabiano, & Massetti, 2005).  These domains may then be used to determine 
treatment goals (Fiks, Mayne, DeBartolo, Power, & Guevara, 2013; Pelham & Fabiano, 2001).  
Caregiver perception of child’s functional impairment may also play a role in decision to initiate 
and continue treatment.  
 Jiang and colleagues (2014) examined functional impairment in ADHD as a predictor of 
treatment acceptability.  Results indicated that greater impairment predicted (using higher linear 
modeling) higher acceptability of combined behavioral and pharmacological treatment.  
However, this result was not found for behavioral or pharmacological treatment in isolation.  
While this finding provides initial support of functional impairment as a predictor of treatment 
acceptability, it is limited by the analog and retrospective nature of study design.   
Specifically, mothers who completed impairment measures were asked to “think of their 
child’s functioning as it would be off medication” (Jiang et al., 2014, p. 536).  This is particularly 
problematic because 75% of the children were currently taking ADHD medication, and 67% of 
those not taking medication at the time of the study, had taken it in the past.  Likewise, these 
mothers may have had to think back several years when rating their child’s behavior as children 
were diagnosed for an average of four years at the time of the study.  Another limitation is that 
mothers were reporting treatment acceptability for a hypothetical child (i.e., not their own); thus, 
no conclusions may be drawn regarding the mothers’ actual treatment decisions.  
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Variables in Current Study 
The current study considered the state of the literature discussed above and the broader 
literature of adherence to childhood chronic illness in selection of predictor variables of 
adherence to ADHD medication outcomes.  Various theories have been proposed to explain why 
individuals do or do not adhere to medical regimens.  Among those most often cited are the 
Health Belief Model (HBM) (Becker, 1974; Janz & Becker, 1984), Social Cognitive Theory 
(SCT) (Bandura, 1986, 1992, 1994), and the Theory of Reasoned Action (TRA) (Ajzen & 
Fishbein, 1980; Fishbein, 1980; Fishbein & Ajzen, 1975).  The current study sought to follow the 
recommendation that the best way to advance the field is to take an integrative approach and 
apply common principles across theories while maintaining unique conceptualizations of specific 
constructs (Rapoff, 2010).  
Predictor variables for the current study were selected for theoretical and 
practical/pragmatic purposes.  First, measuring caregiver perception of child functional 
impairment allows for application of the construct of “perceived severity” in the Health Belief 
Model (HBM; Rosenstock, 1974).  The HBM is a widely studied theory of behavior change that 
has been extended to research on adherence to treatment regimens (Becker, 1974; Bush & 
Iannotti, 1990; Clark & Houle, 2009; Janz & Becker, 1984; Radius, Becker, Rosenstock, 
Drachman, Schuberth, & Teets, 1978; Rapoff, 2010).  Second, as discussed, functional 
impairment is an important component of EBA in ADHD.  Thus, its inclusion is a cost-effective 
approach that may further our understanding of an already established construct.  Third, 
functional impairment is particularly important given its relationship with long-term outcomes. 
A variable examining caregiver response to physician recommendation of medication 
was also included for several other reasons.  First, caregiver report of the physician’s medication 
recommendation as “hasty” allows for application of the construct of “perceived susceptibility” 
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in the HBM.  This construct includes the caregiver belief in or acceptance of a diagnosis (Becker, 
1974; Rapoff, 2010).  Second, given the evolving nature of healthcare that increasingly values 
integration, we selected predictors of potential interest to healthcare providers in general (e.g., 
mental health professionals and physicians).  Third, if the current study suggests these constructs 
have promise as predictors of adherence to ADHD medication, then researchers may consult 
already existing literatures in EBA of ADHD and effective physician-patient interactions (e.g., 
shared decision-making) when considering interventions to alter these attitudes/beliefs.  
Purpose of Study 
 The purpose of the current study was to test a regression model predicting adherence to 
ADHD medication.    
 Study hypothesis.  
Hypothesis 1.  It was expected that recognition by caregivers of child functional 
impairment, as measured by the Vanderbilt Attention-Deficit/Hyperactivity Disorder Parent 
Rating Scale (VADPRS) mean performance score, and report by caregivers of the doctor’s 
recommendation to initiate ADHD medication as “hasty,” as indicated using a visual analog 





Methods and Procedures 
Participants 
Inclusion/exclusion criteria.  Participants recruited for this study were caregivers of 
children who met the following inclusion criteria: (a) six to 12 years of age; (b) had a diagnosis 
made by a physician or psychologist of ADHD-C, ADHD-HI, ADHD-I, or ADHD NOS using 
DSM-IV diagnostic criteria (APA, 2000); and (c) were prescribed an FDA-approved medication 
to treat ADHD within six months from the time of recruitment (see Table 2 for list of eligible 
medications). 
Table 2.  FDA-Approved Medications to Treat Attention-Deficit/Hyperactivity Disorder (ADHD) 
in Children 
Generic Name  Trade Name Approved Age 
amphetamine Adderall 3 and older 





6 and older 
dexmethylphenidate Focalin 6 and older 
dexmethylphenidate (extended release) Focalin XR 6 and older 
dextroamphetamine Dexedrine, Dextrostat 3 and older 
guanfacine
b 
Intuniv 6 and older 
lisdexamfetamine dimesylate Vyvanse
 
6 and older 
methamphetamine Desoxyn 6 and older 
methylphenidate Ritalin 6 and older 
methylphenidate (extended release) Metadate CD, Metadate ER, 
Ritalin SR 
6 and older 
methylphenidate (long-acting) Ritalin LA, Concerta 6 and older 
methylphenidate patch Daytrana 6 and older 
methylphenidate (oral solution and 
chewable tablets) 
Methylin 6 and older 
Note.  
a
Atomoxetine is in a class of medications called selective norepinephrine reuptake 
inhibitors.  
b





Caregivers were excluded from study participation if: (a) they did not speak English; (b) the 
child had a diagnosis by a physician or psychologist of PDD or Mental Retardation (MR) using 
DSM-IV diagnostic criteria (APA, 2000); (c) the child had a diagnosis of a chronic medical 
illness made by a physician that requires daily medication (e.g., asthma); or (d) the current 
ADHD medication trial was not the child’s first (i.e., they had a history of ADHD medication 
prescriptions).  Caregiver participants have been identified as participants and the target children 
(i.e., child who met above eligibility criteria) as children in the remainder of this document. 
Location of study.  Participant recruitment occurred at several locations: four primary 
care outpatient clinics in two academic medical centers, one private primary care outpatient 
clinic, one mental health clinic, multiple Children and Adults with ADD (CHADD) events, and 
via social media.  Physicians in the primary care clinics have provided general pediatric care, 
well-child visits, physicals for sports and other activities, as well as treatment of acute illnesses.  
Two of these clinics have functioned within the Department of Pediatrics of the University of 
Kansas Medical Center (KUMC): Main Clinic on the third floor of the Medical Office Building 
in Kansas City, Kansas, and the University of Kansas (KU) Pediatrics Clinic in Prairie Village, 
Kansas.  The remainder has functioned within the Department of General and Community 
Pediatrics of the University of Oklahoma Health Sciences Center (OUHSC) in Oklahoma City, 
Oklahoma.  The private primary care outpatient clinic has served families in the Lawrence 
Kansas area for several decades.  The mental health clinic has also functioned within the 
Department of Pediatrics of KUMC at the KU Pediatrics Clinic in Prairie Village, Kansas.  
Licensed psychologists who treat the problems of childhood and adolescence using an 
interdisciplinary approach have provided diagnosis and treatment in this clinic.   
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Participants also referred themselves to participate in the study by responding to 
information posted, with permission, on various social media sites (i.e., Facebook pages).  
Recruitment also occurred via the Pioneers Research Participant Registry (RPR) established by 
Frontiers: The Heartland Institute for Clinical and Translational Research, a collaborative 
initiative sponsored by KUMC and other hospitals and universities in the Kansas City, Kansas, 
region (see Appendix A for permission form). 
Informed consent.  Prior to participation in the study, caregiver consent was obtained in 
writing.  Participants obtained the Informed Consent and Authorization to Release Information 
forms approved by the KUMC Human Subjects Committee (HSC) or the OUHSC Institutional 
Review Board (IRB), as appropriate.  Research personnel reviewed these documents with 
participants in person or via telephone.  Research personnel invited caregivers to ask questions 
and/or decline participation.  They emphasized that participation was completely voluntary, may 
be withdrawn at any time without penalty, and did not affect the child’s current or future care 
provided via KUMC or OUHSC.  
Procedures 
Recruitment.  The lead Patient Service Representative (PSR) for the two KUMC 
General Pediatrics Clinics sent the Research Coordinator (RC), via secure email, a copy of the 
schedule of clinic appointments for the upcoming week.  The RC screened all appointments with 
relevant appointment reasons (e.g., F/U Behavior) for eligibility criteria using the electronic 
medical record (EMR).  When available, research personnel attended the appointment for 
potentially eligible patients.  Nursing staff introduced the study to families using an HSC- or 
IRB-approved recruitment flyer (See Appendix B) during the child’s appointment and research 
personnel gave interested families an initial study packet.  Researchers completed informed 
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consent in person as time allowed without disrupting clinic flow.  Otherwise, the RC completed 
the informed consent over the telephone in accordance with HSC or IRB protocol.  Families who 
declined participation were not contacted again.  
A similar procedure was utilized in the KUMC Behavioral Pediatrics clinic.  The RC 
identified potentially eligible families and shared this information with each provider via secure 
email.  Providers then approached the family in clinic to obtain permission for research 
personnel to contact family regarding study participation.  RC then contacted interested families 
by telephone and mailed them an initial study packet.  
For the OUHSC primary care clinic, the RC screened each provider’s appointments for 
potentially eligible patients using the EMR.  Given that research personnel were also clinic staff, 
they were generally able to attend clinic appointments and speak with the family in person.  
Again, researchers completed informed consent in person as time allowed without disrupting 
clinic flow.  Otherwise, the RC completed the informed consent over the telephone in accordance 
with IRB protocol. 
HSC-approved recruitment information was posted, with permission, to various relevant 
social media websites (e.g., local CHADD chapters).  Families interested in participating 
contacted RC by telephone and/or email.  Recruitment then occurred using the procedures 
already outlined.  Research personnel also attended events where the audience was caregivers of 
children or adolescents with ADHD (e.g., CHADD support groups, Executive Function Junction 
Conference).  The Practice Administrator for a private pediatric office in Lawrence, Kansas, sent 
potentially eligible patients an HSC-approved recruitment letter (see Appendix C).  Interested 
families then contacted RC either by email, telephone, or postal mail.  In these instances, we 
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contacted the child’s healthcare provider, via fax and/or phone, to confirm ADHD diagnosis and 
currently prescribed medications (see Appendix D).  
Recruitment also occurred using resources available via KUMC Bioinformatics.  RC used 
the Healthcare Enterprise Repository for Ontological Narration (HERON) to complete a query 
identifying potentially eligible patients from the KUMC EMR.  RC received approval from the 
Data Request Committee (DRC) and obtained information to contact those families identified by 
i2b2 data and registered for the Frontiers Research Participant Registry (Frontiers), a 
comprehensive registry of patients who granted permission to be contacted regarding 
participation in research studies.  RC approached Frontiers patients by telephone using an HSC-
approved script (see Appendix E). 
Baseline.  Participants either completed baseline measures in clinic or at home where 
they were later returned in a preaddressed postage-paid envelope.  Participants completed a 
measure of ADHD symptom severity either during the recruitment appointment or one was 
obtained from the EMR.  In some instances the child had already started taking medication, so 
this measure reflected child’s behavior on medication. 
RC faxed a copy of the Authorization to release protected health information signed by 
the child’s legal representative along with a letter describing the study (see Appendix F) to the 
caregiver-identified pharmacy where the family obtains the child’s medication.  RC faxed these 
prescription history requests either directly to the specific pharmacy location or to the privacy 
office of the larger corporation. 
Follow-up.  Participants who initiated ADHD medication completed the Stimulant 
Adherence Measure (SAM) via telephone approximately one month after study enrollment.  
After completing the SAM interview, participants counted the number of pills remaining in the 
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child’s medication bottle.  Participants completed a second pill count via telephone 
approximately one week after the first.  We calculated a pill count outcome using the following: 
(a) subtracted number of pill counted at Time 2 from the number counted at Time 1; (b) divided 
this product by the total number of pills prescribed over the one-week count interval; and (c) 
multiplied by 100 to obtain a percent of prescribed doses taken (Rapoff, 2010).   
Participants completed follow-up measures using a secure web-based survey (i.e., 
Qualtrics).  Those participants who did not have Internet access, or expressed a preference not to 
complete web-based measures, completed paper-pencil versions of follow-up measures and 
returned them by mail.  RC faxed a second prescription history request to obtain additional 
pharmacy data.   
Measures 
 All non-copyrighted measures for the current study were included in Appendices G 
through I. 
Demographic Questionnaire & Protected Health Information (PHI) Sheet.  
Questionnaires created for the current study collected basic demographic information such as 
age, sex, race/ethnicity, and marital status of primary caregiver.  The questionnaires requested 
various measures of social class including caregivers’ educational level, total family income, and 
school level indicators of poverty (i.e., enrollment in Title I schools) (Diemer, Mistry, 
Wadsworth, López, & Reimers, 2012).  We also collected background variables previously 
found to be associated with willingness to initiate ADHD medication.  Specifically, parents 
reported whether they had other children who have taken ADHD medication (Rostain, Power, & 
Atkins, 1993), and/or an acquaintance that has a child with ADHD (Bennett et al., 1999).  We 
obtained relevant medical information such as specific ADHD diagnosis, date of diagnosis, 
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comorbid mental health diagnoses, and other treatments for ADHD.  PHI was stored separately 
from other study data. 
Medication Recommendation.  A single-item questionnaire created for the current study 
measured the extent to which the caregiver perceives the child’s doctor’s recommendation to 
initiate ADHD medication as “hasty.”  Caregiver response was recorded using a VAS with 0 
centimeters = Completely Agree and 7 centimeters = Completely Disagree.  Qualitative studies 
have consistently reported parental concern and/or negative perception that ADHD medication is 
indiscriminately recommended to children without gathering enough information about the 
individual child (e.g., Brinkman et al., 2009; Charach et al., 2006; Coletti et al., 2012).  To this 
writer’s knowledge, a validated measure of this construct did not previously exist.   
We considered a VAS an appropriate method of measuring this construct for several 
reasons.  First, they have been established as a useful method of measuring subjective constructs 
(e.g., pain, mood, opinion) (Miller & Ferris, 1993; Wewers & Lowe, 1990).  Second, they have 
commonly been regarded as a continuous scale with an approximately normal distribution 
(Miller & Ferris, 1993).  Third, ultimate use of a VAS in a clinic setting has been feasible 
relative to more complex measures (Miller & Ferris, 1993; Wewers & Lowe, 1990). 
Pharmacy Data.  We obtained prescription refill data from the pharmacy (or 
pharmacies) identified by the family as their primary location(s) for obtaining medications.  The 
study utilized a continuous measure of refill adherence focusing on the availability of medication 
calculated using pharmacy data (Steiner & Prochazka, 1997).  We calculated a medication 
possession ratio (MPR) for each participant who accepted a prescription for an ADHD 
medication (Cramer et al., 2008; Marcus & Durkin, 2011).  We calculated MPRs using the 
following: (a) summed the number of days’ supply of medication obtained by refills (according 
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to pharmacy data); and (b) divided the total days from initially filling the ADHD medication 
until the end of study participation.  The MPR was coded as zero for participants who accepted 
(i.e., took prescription from physician), but did not fill the prescription.  The MPR was truncated 
at 1.00 for participants who had a surplus of medication, which likely resulted from dosage 
titration.  We adjusted the MPRs for those participants who indicated they intended to skip 
medications on particular days (e.g., summer vacation, weekends).  Thus, the study accounted 
for planned drug holidays. 
 SAMBA.  The SAMBA scales measures child (ages five to 18 years) and parent attitudes 
toward ADHD medications (Harpur, Thompson, Daley, Abikoff, & Sonuga-Barke, 2008).  
Authors derived scales from principle components analysis with each factor having an 
eigenvalue > 1.0.  The child version has 16 items comprising four scales: (a) perceived costs of 
medication; (b) perceived benefits of medication; (c) child stigma; and (d) resistance.  All scales 
have been found to have acceptable internal consistency reliability ( > 0.70).  The parent 
version has 27 items comprising seven subscales: (a) perceived costs of medication; (b) 
perceived benefits of medication; (c) child stigma; (d) parent stigma; (e) child resistance; (f) 
dosing flexibility; and (g) parent medication-related inconsistency.  All scales but one, parent 
medication-related inconsistency ( = 0.67), have been shown to have acceptable internal 
consistency reliability ( > 0.70).  Respondents are asked to consider how true each 
questionnaire item is to their experience over the last three months of treatment.  Both versions 
use a five-point Likert scale anchored with 1 = Strongly Disagree and 5 = Strongly Agree.   
 Positive and significant correlations between parent and child report have been reported: 
costs (r = .70), benefits (r = .41), child stigma (r = .70), and resistance (r = .57). Nevertheless, 
children reported significantly more costs and fewer benefits of ADHD medication than parents 
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(Benefits t(108) = 5.60; p < 0.001; Costs t(105) = 3.31; p < 0.001).  The current study used only 
the parent version for multiple reasons.  First, while child self-report is important, the current 
study was primarily interested in caregiver beliefs/attitudes as the ultimate decision-makers for 
this age group (Charach, Yeung, Volpe, Goodale, & dosReis, 2014; Hoza et al., 2006).  Second, 
we decided that the reading and cognitive level of the child report was beyond the common 
abilities of children of this age. 
 SAM.  The SAM is a semi-structured telephone interview designed to measure adherence 
to ADHD medication in children (Charach, Gajaria, Skyba, & Chen, 2008).  The SAM is 
intended to be conversational and uses nonjudgmental language to elicit information regarding 
ADHD medication usage.  Interviews with a parent and child are conducted separately and 
require approximately five to 15 minutes to complete.  Parent respondents are asked to estimate 
how many pills their child missed over the past seven and 28 days.  Child respondents are asked 
to report how many pills they missed over the past seven days only.  We included only the parent 
version in the current study.  
 Charach and colleagues (2008) compared parent and child (ages eight to 15 years) report 
(n = 22) families using the Medication Event Monitoring System (MEMS) and the SAM each 
month for three months.  Results indicated good to excellent agreement between the MEMS and 
SAM parent report (ICCs = 0.663 to 0.907) and good agreement between the MEMS and SAM 
child report (ICCs = 0.542 to 0.773). Inter-rater reliability between ratings made by the original 
interviewer and a second rater who coded based on audiotape was excellent (ICCs = 0.927 to 
0.956).  The SAM appears to be a stable measure as no significant differences were found 
between interviews at months one, two, or three. 
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 VADPRS.  The VADPRS is an ADHD symptom rating scale based on DSM-IV criteria.  
The VADPRS includes 47 items assessing symptoms of ADHD-I, ADHD-HI, ODD, CD, as well 
as anxiety and depression.  The last eight items evaluate impairment in academic performance 
and interpersonal relationships.  Parents are instructed to consider what is age appropriate when 
completing ratings.  They use a four-point Likert scale anchored with 0 = Never and 3 = Very 
Often to rate how often their child exhibited various behaviors in the past six months.  Items 
rated a 2 or 3 are considered positive responses.  The performance items are rated using a five-
point Likert scale anchored with 1 = Excellent and 5 = Problematic.  Items rated a 4 or 5 are 
positive responses indicative of impairment.  The VADPRS is scored by adding the number of 
positive responses in each domain and calculating a mean performance score. 
 The VADPRS is included as part of the AAP and NICHQ ADHD Toolkit (AAP & 
NICHQ, 2002), and is established as a measure for EBA of ADHD (AACAP Work Group on 
Quality Issues, 2007; Pelham et al., 2005).  The VADPRS has demonstrated good internal 
consistency ( = 0.94 to 0.95), and fit with a four-factor model using confirmatory factor 
analysis (ADHD-I, ADHD-HI, Externalizing Problems, Internalizing Problems)(Wolraich et al., 
2003).  The VADPRS is easy to read at slightly below third grade level (Wolraich et al., 2003).  
A version of the scale to be completed by a teacher is also available (Wolraich, Feurer, Hannah, 
Baumgaertel, & Pinnock, 1998). 
 The study calculated descriptive statistics for each of the following VADPRS summary 
scores: (a) number of positive responses to ADHD-I items; (b) number of positive responses to 
ADHD-HI items; (c) total symptom score for ADHD items; (d) number of positive responses to 
ODD items; (e) number of positive responses to CD items; (f) number of positive responses to 
anxiety and depression items; (g) number of positive responses to performance items; and (h) 
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mean performance score.  These data indicated the severity of ADHD in the sample.  The mean 
performance score for those measures reflecting child’s behavior off medication was included in 
regression analyses as a measure of functional impairment. 
Statistical analyses 
Missing data.  Given the small sample size, we did not have enough information to use 
any methods to account for missing data (e.g., multiple imputation).   
Analysis of results.  We completed all analyses using the Statistical Package for Social 
Sciences (SPSS, Armonk, NY) version 21.  The RC entered data.  Prior to conducting analyses, 
we double-checked that all data were entered correctly.  We did not check for assumptions of 
normality as the small sample size did not allow for this.  Thus, we used non-parametric 
alternatives that do not rely on an assumption of normality.  Given the preliminary nature of the 
current study, alpha level was set at  = .10. 
Preliminary analyses.  We utilized the One-Sample Wilcoxon Signed Rank Test to 
compare adherence rates in the current sample against those that have been reported in the 
literature.  We used the reported mean as our null hypothesized median, as there was no 
alternative because studies did not provide median levels.  We used the Independent-Samples 
Mann-Whitney U Test to assess for significant differences in a continuous outcome between two 
independent groups within the current sample.  We assessed demographic and condition-specific 
variables for relation to primary dependent measure (i.e., MPR) using Kendall’s tau as the 
correlation measure because it does not require data to be normally distributed or the relationship 
between variables to be linear. 
Hypothesis 1.  We performed a standard multiple regression using the forced entry 
method between MPR as the dependent variable and the following as independent variables 
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(IVs): demographic and/or condition-specific variables that significantly correlated with MPR, 
recognition by caregivers of child functional impairment, and report by caregivers of the doctor’s 
recommendation to initiate ADHD medication as “hasty.”  Only those VADPRS measures 
completed when child was not on medication were included in this analysis.  In order to prevent 
issues of multicollinearity, we assessed for significant correlations between IVs prior to 
including them in regression analyses.  We included bootstrapping using the bias corrected and 
accelerated method for calculating 95% confidence intervals, which were used to test the null 






 Recruitment.  We actively recruited participants from July 2, 2013 to November 3, 
2014.  Of 165 families approached, 112 did not meet eligibility criteria (see Figure 1).  The 
majority (i.e., 67%) of these families did not meet eligibility criteria due to ADHD medication 
history: 27 children had taken a different ADHD medication in the past; 35 children did not meet 
the original time criterion of having been prescribed ADHD medication within one month of 
recruitment; and 13 did not meet the revised time criterion of having been prescribed ADHD 
medication within six months of recruitment.  Fifteen of the families approached declined 
participation.  The remainder (n = 21) could not be contacted to complete informed consent.  
Participants were recruited from the following sources: 10 from OUHSC; four from KUMC 
Behavioral Pediatrics clinics; two from CHADD events; and one from KUMC Primary Care 
clinics. 
 Participant characteristics.  Of the 14 participants, the majority was female (92.86%), 
had an annual household income lower than $50,000 (64.7%), and had obtained greater than a 
high school education (70.6%).  Half of the participants were married.  Participants’ age at study 
entry ranged from 27.39 to 63.22 years (M = 37.78, SD = 9.04).  Age at study entry for 
participants’ partner (i.e., most often child’s father) ranged from 30.55 to 51.44 years (M = 
37.70, SD = 6.96).  Six participants (35.3%) had children, other than the target child, who had 
taken ADHD medication.  Eight participants (47.1%) had a family member, friend, or 
acquaintance that had a child who has taken ADHD medication.   
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Figure 1. Participant enrollment. 
 
 
The majority of the children were male (70.6%), currently attending school below third 
grade (52.9%), at a low-income, Title 1 school (52.9%).  Of those attending a Title 1 school, the 
percent of children at the school considered low-income ranged from 49.20 to 98.40 (M = 80.96, 
SD = 17.07).  Five children (29.4%) were non-Hispanic White.  Age at study entry for target 
child ranged from 6.16 to 12.09 years (M = 8.80, SD = 2.04).  A psychologist, as opposed to 
physician, diagnosed a majority of the children with ADHD (47.1%).  The majority of children 
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were prescribed a CNS once per day (47.1%).  Age at time of ADHD diagnosis for child ranged 
from 5.83 to 11.72 years (M = 7.81, SD = 1.70), and age at start of ADHD treatment ranged from 
5.90 to 11.72 years (M = 7.92, SD = 1.72).  The majority of children had used evidence-based 
treatment (64.7%), not including FDA-approved medication, to treat ADHD.  The majority of 
children had also used non-evidence-based treatment (64.3%). See Tables 3 and 4. 
Table 3.  Categorical Demographic Variables (N = 14) 
Variable n (%) 
 
Caregiver Sex 
 Male 13 (93%) 
 Female 1 (7%) 
 
Marital Status 
 Single 3 (21%) 
 Married 7 (50%) 
 Divorced 1 (7%) 
 Not Married, Live with Partner 3 (21%) 
 
Household Income 
 $0-$10,000 2 (14%) 
 $10,001-$30,000 1 (7%) 
 $30,001-$50,000 8 (57%) 
 $50,001-$70,000 2 (14%) 
 $70,001-$100,000 0 (0%) 
 Above $100,001 1 (7%) 
 
Education 
 High School Graduate 2 (14%) 
 Some College or Specialized Training 8 (57%) 
 College Graduate 4 (29%) 
 
Child Sex 
 Male 12 (86%) 
 Female 2 (14%) 
 
Child Race 
 Black or African American 4 (29%) 
 White 1 (7%) 
 Multiracial 9 (64%) 
 
Child Ethnicity 
 Not Hispanic or Latino  8 (56%) 
 Hispanic or Latino 6 (43%) 
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Table 4.  Continuous Demographic Variables (N = 14) 
Variable M SD 
 




 37.70 6.96 
 
Child Age  8.80 2.04 
 
Child Age at Diagnosis
a
 7.81 1.70 
 
Child Age at Start of Treatment
a
 7.92 1.72 
Note. 
a
n = 13. 
ADHD symptoms and impairment.  Nine participants completed the VADPRS when 
the child was not on ADHD medication.  As expected, results from these reports differed 
significantly from those of participants whose child was already on medication (See Table 5).  
For the stimulant naïve children, the number of positive responses (i.e., rated “Often” or “Very 
Often”) to ADHD-I and ADHD-HI items, respectively, ranged from six to nine (M = 8.38, Mdn 
= 9.00, SD = 1.06) and one to nine (M = 6.33, Mdn = 7.00, SD = 3.12).  The Total ADHD 
Symptom Score ranged from 28 to 50 (M = 41.00, Mdn = 44.00, SD = 8.57).  Of note, the 
number of positive responses to ODD items ranged from zero to eight (M = 4.00, Mdn = 4.00, 
SD = 2.98) with a mean indicative of a positive screening (i.e., requires four of eight items to be 
positive; AAP & NICHQ, 2002).  One participant reported on the Demographic Questionnaire 
that the child had a comorbid diagnosis of ODD.  One participant also reported that the child had 
a comorbid diagnosis of Generalized Anxiety Disorder.  However, overall results did not indicate 
a positive screening for anxiety and depression (M = 1.38, Mdn = 1.50, SD = 1.41).  When 
considering functional impairment, the number of positive responses (i.e., rated “Somewhat of a 
Problem” or “Problematic”) to Performance items ranged from one to five (M = 3.67, Mdn = 
4.00, SD = 1.66).  The Mean Performance scale ranged from two to four (M = 3.40, Mdn = 3.63, 
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SD = .64).  These results are comparable to those reported elsewhere for children with ADHD 
and higher than for children with no diagnosis (Becker, Langberg, Vaughn, & Epstein, 2012).   
Table 5.  Vanderbilt ADHD Diagnostic Parent Rating Scales 
 Off Medication
a
 On Medication p
b 
Variable M  Mdn SD M  Mdn SD 
 




 n 8 5 
 
Positive Responses to 6.33  7.00 3.12 4.20 2.00 3.03 .364 
ADHD-HI Items  
 n 9 5 
 
Total Symptom Score 41.00  44.00 8.57 27.00 31.00 8.60 .045* 
for ADHD Items  
 n 8 5 
 
Positive Responses to 4.00  4.00 2.98 .60 0.00 .89 .030* 
ODD Items  
 n 8 5 
 
Positive Responses to  1.25  1.00 1.49 .20 0.00 .45 .171 
CD Items  
 n 8 5 
 
Positive Responses to  1.38  1.50 1.41 1.60 1.00 1.82 1.00 
Anx. & Dep. Items  
 n 8 5 
 




 n 9 5 
 
Mean Performance Score 3.40  3.63 .64 2.93 2.88 .40 .147 
 n 9 5 
Note.  ADHD-HI = ADHD-Hyperactive/Impulsive.  ADHD-I = ADHD-Inattention.  Anx. = 
Anxiety. CD = Conduct Disorder.  Dep. = Depression. ODD = Oppositional Defiant Disorder.  
a
Child was on or off medication when measure was completed.  
b
Independent-Samples Mann-
Whitney U Test.  
c
Positive responses to symptom items are those rated “Often” or “Very Often.” 
d




 Three participants completed the VADPRS follow-up measure of child’s behavior while 
on medication.  These results were lower than the initial report.  The number of positive 
responses to ADHD-I and ADHD-HI items, respectively, ranged from zero to five (M = 1.67, 
Mdn = .00, SD = 2.89) and zero to nine (M = 3.33, Mdn = 1.00, SD = 4.93). The Total ADHD 
Symptom Score ranged from 15 to 50 (M = 24.67, Mdn = 19.00, SD = 15.31).  The number of 
positive response to Performance items ranged from zero to one (M = .67, Mdn = 1.00, SD = 
.58).  The Mean Performance scale ranged from 2.13 to 3.13 (M = 2.67, Mdn = 2.75, SD = .51). 
Preliminary Analyses 
Adherence.  We obtained pharmacy data, which allowed us to calculate MPRs, for 14 
participants.  The number of days included in the MPR ranged from 22 to 307 (M = 164.45, SD = 
100.01).  MPR ranged from 0.00 to 1.00 (M = .65, SD = .38).  The median (Mdn = .75) was not 
significantly different from what has been reported in the ADHD medication adherence literature 
(Mdn = .49), T = 1.795, p = .07 (Gajria et al., 2014). The MPR for three participants was coded 
as 0.00 because they accepted, but did not fill a prescription for ADHD.  When excluding these 
participants, MPR ranged from .56 to 1.00 (M = .83, SD = .17).  The median (Mdn = .80) was 
significantly higher from what has been previously reported (Mdn = .49), T = 2.675, p = .007 
(Gajria et al., 2014). 
 Five participants completed the SAM.  Participant recall for number of doses missed 
during the past seven days ranged from zero to four (M = .80, Mdn = .00, SD = 1.79).  Number of 
doses missed during the past 28 days ranged from zero to 16 (M = 3.80, Mdn = .00, SD = 6.94).  
However, participants accounted for missed doses by describing them as planned drug holidays.  
Accounting for these resulted in 100.00% adherent for all participants over the past week and 
95.00 to 100.00% (M = 99.00, Mdn = 100.00, SD = 2.24) over the past 28 days.  Four of these 
five participants also completed a pill count outcome.  One participant explained that she did not 
  
 47 
have access to the child’s medication as it was kept at school.  Percent adherent according to pill 
count ranged from zero to 93.33 (M = 57.96, Mdn = 69.26, SD = 42.71).  Adherence outcomes 
for each participant are included in Table 6. 
Table 6.  Percent Adherence for Participants with Multiple Measures 




100.00 100.00 51.85 55.56 (162) 
100.00 100.00 - 100.00 (28) 
100.00 100.00 93.33 100.00 (41) 
100.00 95.00 0.00 68.00 (307) 
100.00 100.00 86.67 100.00 (203) 
Note.  SAM – 7 = Stimulant Adherence Measure – Doses missed past seven days.  SAM – 28 = 
Stimulant Adherence Measure – Doses missed past 28 days.  MPR = Medication possession 
ratio.  
a
Number of days included in MPR. 
 
 Medication Recommendation.  Fourteen participants completed the VAS measuring the 
extent to which they perceived the child’s doctor’s recommendation to initiate ADHD 
medication at “hasty.”  Responses ranged from zero (i.e., “Completely Agree”) to seven (i.e., 
“Completely Disagree;” M = 5.24, SD = 2.36).  The median was 6.80 with a mode of 7.0.  The 
distribution of this measure differed significantly between participants who did (M = 6.11, Mdn 
= 7.00, SD = 1.63) and did not (M = 2.07, Mdn = 2.50, SD = 1.89) fill a prescription of ADHD 
medication for the child, T = 2.350, p = .022. 
SAM.  Five participants completed the SAM.  Participants generally reported that the 
child was doing well with ADHD medication.  One participant discussed her decision to allow 
her child drug holidays over the weekend.  Two participants reported that the child was not 
experiencing any medication side effects.  Of the three participants who reported side effects, 
three reported experiencing loss of appetite, two reported experiencing sleep difficulties, one 
reported experiencing headaches, and one reported experiencing tics.  One participant identified 
the child’s emotional labiality as an additional side effect.  Two participants stated that they 
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considered stopping the medication.  The child of both of these participants had been taking 
ADHD medication longer than the mean for the current sample.  Two participants who stated 
they had not considered stopping the medication cited the child’s improvement as a reason.  All 
participants reported forgetting to give child ADHD medication less than once per month.  See 
Table 7 for details. 
 SAMBA.  Five participants completed the SAMBA.  Results were similar to those 
reported by the scale developers (Harpur et al., 2008).  The subscale with the highest mean was 
Benefits (M = 14.80, SD = 3.11).  The subscale with the lowest mean was Child Stigma (M = 
5.60, SD = 1.67).  The mean for other subscales ranged from 7.60 (Resistance) and 9.80 (Parental 
Stigma).  See Table 8 for details. 
Table 8.  Southampton ADHD Medication Behaviour and Attitudes Scale 
Subscale Min Max M Mdn SD 
 
Benefits 11 18 14.80 14.00 3.11 
Costs 4 15 8.40 8.00 4.16 
Resistance 6 8 7.60 8.00 .89 
Child Stigma 4 8 5.60 6.00 1.67 
Parental Stigma 4 15 9.80 12.00 5.40 
Flexibility 4 15 8.80 10.00 4.44 
Inconsistent 3 8 4.60 4.00 2.07 
Note.  N = 5. 
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Table 7.  Excerpts from Stimulant Adherence Measure 
Interview question Participant Response 
How is (child’s name) doing 
with the ADHD medication? 
“He is actually doing pretty good.  He’s still a bit 
hyperactive.  They changed the medication, so he’s taking 
more.” 
 
 “He is doing very well.” 
 
 “Doing OK.  He’s definitely got more focus, but it either 
wears off really quickly.  He can sit and do his schoolwork 
for about 30 minutes, but he’s like a bunny everywhere.” 
 
 “So so.  We actually go see his doctor next Thursday to 
discuss it because it’s wearing off by 4 or 5pm.  Going to 
bed is becoming an issue.  We get up at 5:30 every 
morning.” 
 
 “The medication is good.  He does really well when it’s 
on, but things get hard when it wears off in the afternoon.” 
 
What made you decide to 
not give (child’s name) their 
medication on weekends? 
“Him being on medication was a big thing for me.  I just 
don’t want my kids on medication.  But weekends I just 
let him be a kid.  Because I know medications restrict him 
from things he wants to do.  He’s got energy to burn.” 
 
Is (child’s name) 
experiencing loss of 
appetite?  If yes, do you 
think this is related to the 
medication? 
“Yes.  Severe loss of appetite.  He was basically like a 
garbage disposal before meds.”  
 
“Yes and no.  We usually try to feed him before he takes 
his pill in the morning.  He doesn’t usually eat lunch.  
He’s hungry by dinner, but starving at bedtime.” 
 
 “Yes.  It seems to suppress his appetite for awhile, but 
once it wears off he is the same.” 
 
Is (child’s name) 
experiencing headaches?  If 
yes, do you think this is 
related to the medication? 
 





Table 7 Continued.  Excerpts from Stimulant Adherence Measure 
Interview question Participant Response 
Is (child’s name) 
experiencing trouble getting 
to sleep or staying asleep?  
If yes, do you think this is 
related to the medication? 
 
“Yes, but he’s always had trouble with sleep.” 
 
“Yes, he’s had trouble here and there.  He is a 
sleepwalker.  He occasionally gets up and comes to our 
room. And he couldn’t make his mind slow or stop.” 
 
Is (child’s name) 
experiencing tics?  If yes, do 
you think this is related to 
the medication? 
 
“Yes, he has to have something in his mouth at all times.  
He will chew on his shirt if he doesn’t have anything else.  
He chews bubblegum in class to prevent this.” 
Is child experiencing any 
other side effects? 
 
“Yes, he’s very emotional.  Like a rollercoaster.  He might 
get in trouble for the slightest thing and have a 
meltdown.” 
 
Have you ever thought 
about stopping the 
medication? Why or why 
not? 
 
“No because he’s doing better now. 
 
“No, because it’s helping him.  He’s doing better in school 
now than without.” 
 
“No.  We just started it.  We’ve thought about different 
medications because this one doesn’t work with 
hyperactivity.” 
 
“Yes, because we try to weigh the good with the bad.  
From the emotional stuff and having to comfort him or it’s 
bouncing off the walls.  Has no concentration or self-
control.  
 
“Yes.  Sometimes when he’s on the med he seems 
depressed.  I don’t see any feelings or excitement.” 
 
How often do you think you 
forget to give your child 
their medication, for 
example because it’s a busy 
time of year or a hectic 
morning? 
“I do forget sometimes, but he remembers.” 
 
“Before I started keeping it at the school, would be once 
per month. But now, not at all.” 
 




“Several times in the beginning, but in the last two months 




 Correlations.  There was a significant negative correlation using Kendall’s tau between 
the number of days included in the MPR and the primary adherence outcome (i.e., MPR), τ = – 
.41, p (one-tailed) = .05.  There were significant relationships between demographic variables 
and MPR.  Specifically, percent of children at Title 1 school considered low-income, τ = – .50, p 
(two-tailed) = .07, and highest grade-level completed by participant being greater than high 
school, τ = – .41, p (two-tailed) = .10 were negatively correlated with MPR.  VADPRS mean 
Performance score was not significantly associated with MPR, τ = .03, p (one-tailed) = .39, nor 
was number of positive responses to Performance items, τ = .17, p (one-tailed) > .34.  Report by 
participants of the doctor’s recommendation to initiate ADHD medication as “hasty” was not 
significantly associated with MPR, τ = .19, p (one-tailed) > .19.  The following variables were 
also not significantly correlated with MPR: marital status of participant; participant has another 
child with ADHD medication; participant has a family member, friend, or acquaintance that has 
a child who has taken ADHD medication; household income; child health insurance; child 
gender; child grade level; child Race/Ethnicity; education of child’s father; child’s age; 
participant’s age; age of child’s father; use of evidence-based or non-evidence-based treatment; 
child age at ADHD diagnosis; child age at start of ADHD treatment; and remaining VADPRS 
scales. 
Study Hypothesis 
 Hypothesis 1.  Given the negligible correlations between hypothesized predictors (i.e., 
mean Performance score, medication VAS), they were not included in regression analyses.  
Standard multiple regression was performed with variables that significantly correlated with 
MPR (i.e., number of days included in MPR, participant education, and percent of children at 
Title 1 school considered low-income) as predictors.  No adjustments for multicollinearity were 
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necessary as none of these IVs significantly correlated with each other.  A solution with three 
IVs was not significant, F = 3.260, p = .14, ∆R
2 
= .492.  A solution using number of days 







 The hypothesis that recognition by caregivers of child functional impairment and report 
by caregivers of the doctor’s recommendation to initiate ADHD medication as “hasty” would 
account for statistically significant variance in adherence to ADHD medication was not 
supported.  None of these predictor variables were significantly associated with the outcome 
variable (i.e., MPR).  Unfortunately, the conclusions that may be drawn from this finding are 
limited as this study was underpowered (Cohen, 1992).  Nevertheless, the correlations were in 
the hypothesized directions.  Most notably, as participants disagreed with the statement, “My 
child’s doctor was too hasty in his/her recommendation of ADHD medication,” their adherence 
outcome increased.  This finding provides preliminary data to suggest that caregivers’ perception 
of their child’s doctor as “hasty” in their recommendation of ADHD medication is related to 
actual adherence behavior.  To this writer’s knowledge, this is the first study to report this 
relationship using objective adherence data and not only caregiver report (Ahmed et al., 2013). 
Thus, clinicians who wish to improve adherence to ADHD medication in children may do 
so by working toward improving interactions between physician and caregivers.  Improving the 
quality or effectiveness of these interactions may be influenced by increasing shared decision-
making between physician and caregivers (Butler, 2014; Charles et al., 1999; Fiks et al., 2011; 
Lipstein, Dodds, & Britto, 2014; Lipstein, Brinkman, & Britto, 2012).  Some studies have 
provided initial evidence of the efficacy of interventions promoting shared decision-making in 
the context of childhood ADHD (Brinkman et al., 2013; Chow, Sciberras, Gillam, Green,  & 
Efron, 2013; Davis, Claudius, Palinkas, Wong, & Leslie, 2012).  If the current study is replicated 
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in studies with greater statistical power, then this would provide further theoretical basis of the 
importance of establishing effective shared decision-making interventions. 
The current study examined caregiver predictors of adherence to ADHD medication for 
school-aged children.  Findings are similar to other ADHD medication adherence studies and the 
general pediatric adherence literature in several ways.  First, higher poverty level and lower level 
of caregiver education were found to be associated with lower adherence.  Similar associations 
between measures of socioeconomic status and adherence have been documented in studies 
specific to ADHD (e.g., Ibrahim, 2002) and other chronic conditions (e.g., Brownbridge & 
Fielding, 1994; Radius et al., 1978; Rapoff, Belmont, Lindsley, & Olson, 2005).  However, these 
associations have not always been found in ADHD-specific studies (e.g., Gau et al., 2006; 
Johnston & Fine, 1993).  Second, longer treatment duration (i.e., number of days included in 
MPR) was associated with lower adherence, which has also been demonstrated in other chronic 
conditions (e.g., Brownbridge & Fielding, 1994; Kovacs, Goldston, Obrosky, & Iyengar, 1992; 
Rapoff, et al., 2002). 
Third, this study inadvertently focused solely on CNS medications as this was the only 
medication class prescribed to children.  Gajria and colleagues (2014) noted the preponderance 
of studies on CNS medications only.  Fourth, caregiver attitudes or beliefs were not found to be 
significantly related to medication adherence.  While it would be premature to conclude that 
these variables are not associated with adherence to ADHD medication, it is not unusual for 
attitudes or beliefs to not account for significant variance in health-related behaviors (Clark & 
Houle, 2009; Janz & Becker, 1984; Rapoff, 2010).  The current study did not find the often-
reported improvement in adherence associated with long-acting CNS or once daily medications 




Limitations.  While the current study is preliminary in nature, results must be considered 
in context of several limitations.  First, the small sample size limits the power of the study and 
the generalizability of results.  It is unclear whether support for the study hypothesis was not 
found because it truly does not exist or if the amount of available data was too small to find an 
effect.  The large percent of families approached who were ineligible to participate (i.e., 67.88%) 
also limits the conclusions that may be drawn about the population of children with ADHD.  
Furthermore, all but one participant was a female caregiver, which perpetuates the lack of male 
caregivers in similar studies (Singh, 2003).  Second, while this study reported information on 
whether child was currently receiving mental health treatment, we are not able to suggest how 
this may influence caregiver’s decisions regarding ADHD medication. 
Strengths.  The current study has improved on previous studies in several ways.  First, it 
was specifically designed to examine adherence to ADHD medications.  Several studies were 
initially designed to evaluate treatment outcome and subsequently included investigation of 
medication adherence (e.g., Faraone et al., 2007; Gau et al., 2006).  Second, the current study 
was not solely retrospective as several previous studies have been (e.g., Atzori, Usala, Carucci, 
Danjou, & Zuddas, 2009; Olfson, Marcus, & Wan, 2009; Winterstein et al., 2008) and included 
relatively adequate follow-up on medication adherence (M = 164.45, Mdn = 194.00, SD = 
100.01).  Third, it did not include any analog methodology as others have (e.g., Jiang et al., 
2014).  Fourth, the current study included multiple measures of adherence (Quittner et al., 2008; 
Rapoff, 2010), and accounted for planned drug holidays (Faraone et al., 2007; Rapoff, 2010).  
Fifth, the current study was theory-driven with an a priori hypothesis, and was designed to 
inform clinical practice.  While the current study has been explicative in nature (i.e., clarifies 
relationships among variables associated with poor adherence to ADHD medication), it also 
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emphasized integration with intervention research and clinical utility of results (Roberts, 1992; 
Roberts, McNeal, Randall, & Roberts, 1996).  Finally, the study included data regarding 
presence and severity of ADHD symptoms and comorbid disorders. 
Future Directions 
 Recruitment.  Difficulty recruiting for the current study led to learning several lessons 
that may improve future efforts.  First, while a “clean” sample meeting several eligibility criteria 
is appealing, it may not be necessary in studies of adherence outcomes rather than treatment 
outcomes.  For example, we postulated that caregivers that have experienced medication 
switching, especially when due to adverse effects, may have attitudes or beliefs that differ from 
caregivers who are on their first ADHD medication trial.  However, the current state of the 
literature is such that we know little about the relationship between caregivers’ attitudes or 
beliefs and ADHD medication adherence in general.  Thus, it may be premature to attempt to 
delineate these variables between groups of caregivers especially given potentially high rates of 
medication switching (3.7% to 59%; Gajria et al., 2014).  Second, while the current study 
included several strategies for minimizing attrition (including enrollment refusal), incorporating 
specific additional strategies may be beneficial (Karlson & Rapoff, 2007).  For example, 
providing participant incentives and minimizing participant burden especially by incorporating 
data collection into routine clinic visits appear to be promising.  Of note, the majority of 
participants enrolled in the current study were recruited from a primary care location that readily 
allowed research personnel to be present in clinic.  Nevertheless, time and concerns regarding 
clinic flow remained a barrier to completing study measures during the clinic appointment when 
families were initially approached about study participation.  Third, while research databases 
such as the Pioneers RPR used in the current study, show promise as a recruitment tool, they 
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may be a less appropriate source for studies on “controversial” topics such as ADHD medication.  
The majority (67%) of families who declined participation were approached via the RPR.  Many 
caregivers were not familiar with the registry and did not recall signing up for it.  Furthermore, 
several caregivers made statements such as, “I’m not interested in anything that has to do with 
medicating my child.”  
Measurement considerations.  Future studies should continue to include multiple 
measures of adherence.  Studies with a larger sample size (e.g., ≥ 120 participants) may be 
designed to use higher linear modeling to examine convergence between multiple measures of 
adherence. Future studies may also consider using a measure of functional impairment that 
provides outcomes that are continuous as opposed to ordinal (e.g., Fabiano et al., 2006).  This 
measure may be used in addition to a symptom rating scale, such as VADPRS, to allow for more 
thorough assessment of the relationship between functional impairment and medication 
adherence.  The Medication Recommendation VAS appears to be a promising measure of 
caregivers’ perception of doctors’ medication recommendations and may continue to be used in 
future studies.  Given a larger sample size, it is likely this VAS will be normally distributed, 
which would allow for more powerful statistical analyses.  While attitudes and beliefs may play a 
role in medication adherence, future studies should incorporate measures of barriers to adherence 
as these behavioral constructs have been found to be the most robust predictor across studies of 
the HBM (Becker, 1974; Janz & Becker, 1984; Rapoff, 2010). 
Summary and Conclusions 
Childhood ADHD is a significant public health issue as it is a disorder with a high 
prevalence and negative consequences (Visser et al., 2014).  Well-established psychosocial and 
pharmacological treatments are available.  However, approximately 30% of families prescribed 
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an ADHD medication may not fill it (Demidovich et al., 2011).  Those who initiate medication 
commonly discontinue use within six months or have poor adherence (Gajria et al., 2014).  The 
work of researchers, clinicians, and public health administrators alike may be improved by 
further understanding of the complex relationships between caregiver and child/adolescent 
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Frontiers Research Participant Registry Permission Form 
FRONTIERS: Heartland Institute for Clinical and Translational Research 
Permission for Contact about Future Research Studies 
 
Physicians and other researchers at KU Medical Center (KUMC) conduct research to make new 
discoveries and promote the health of our patients.  We are asking for your permission to 
contact you if there is a research study for which you, your child or the person for whom 
you are making decisions might qualify.  Only authorized researchers with approved studies 
may request a list of patients willing to be contacted. 
 
The University of Kansas Physicians, KU Hospital and KU HealthPartners will allow authorized 
researchers to use information in your records to identify potential study participants. We will 
use information such as diagnosis codes, dates of medical events or procedures, current 
medications, age, ethnicity, gender and zip code to determine which studies might be applicable 
to you or the person for whom you are signing.  Authorized researchers will be given only 
contact information (e.g.,name, e-mail address, mailing address and phone number) of 
individuals who may qualify for a study, and they will provide you with details about the study.  
You are free to say yes or no to any study. 
 
The privacy of your health information is covered by the Federal Health Insurance Portability 
and Accountability Act (HIPAA).  While some researchers are not required to follow the HIPAA 
rules, if they disclose your information, there may be other laws that protect your information 
from improper use. 
 
Signing this form is completely voluntary. If you do not want to be contacted about research, do 
not sign this form.  Choosing not to sign will have no effect on the care and services you, your 
child or the person for whom you are signing receives at KUMC. 
 
This form also allows you to receive information via e-mail. There are risks associated with 
communications via e-mail. For instance, there is a risk that e-mail communications could be 
intercepted or sent to unintended parties.  Our current policy is to send e-mails that contain 
health information through a secured system. This system will require you to create a new user 
name and password to access your e-mail on our servers. Our policy may change in the future to 
allow e-mails that contain health information be sent unsecured, like regular email. 
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If you want all email to be sent unsecure (if the policy changes), like regular e-mail, initial here:  
_______ 
If you do not want to receive any communications via e-mail, initial here:  _______ 
 
________________________________  ____________________________ _________  
Signature of Patient      Print Patient Name   Date 
 
________________________________ _____________________________ ________ 
Signature of Parent or Legal Guardian  Print Name of Parent/Guardian and  Date 
Relationship 
       
________________________________   ___________________________ 
E-mail Address      Date of Birth 
 
You will receive a copy of this signed form.  This permission for contact will stay in effect 
indefinitely, unless you cancel it.  To cancel your permission, write to Richard Barohn, MD; 
Director, Frontiers: The Heartland Institute for Clinical and Translational Research; University 
of Kansas Medical Center, Mail Stop 6011; 4350 Shawnee Mission Pkwy; Fairway, KS 66205. 
If you cancel your permission, we will make the change in our records for future reference.  If 
you have any questions about being contacted about research, please call the Frontiers Office at 
913-588-6290.  If you take the form home for review, make a copy and mail the signed form 















Predictors of Initiating and Adhering to Medication for 
Attention-Deficit/Hyperactivity Disorder in Children 
 
As a parent of a child between six and twelve years of age with attention-
deficit/hyperactivity disorder (ADHD), you are being invited to participate in a study 
on parents’ attitudes toward ADHD medication.  We know some of the things parents 
say they think about when deciding to give their child ADHD medication.  We want to 
know more about how these things relate to filling a new prescription for ADHD 
medication and to giving this medication over time. 
Study activities will include completion of brief questionnaires and three telephone 
interviews.  Your child's medications will not change for the purpose of this study.  You 
will NOT need to have any extra visits to the clinic.    
Your participation in this study is voluntary. Not participating will have no effect 
upon the medical care or treatment your child receives now or in the future at the 
University of Kansas Medical Center or at Pediatric and Adolescent Medicine. 
If you are interested in participating in this study, please contact Catrina Litzenburg 
at (913) 588-2042 and leave your name and phone number.  You can also email Catrina 
at email address clootens@kumc.edu.  Study staff will respond with more information. 
 
If you would prefer to mail in this form, please fill out the below fields:  
Best Contact Phone Number:_____________________ 
Best Time to be reached: _____________________ 
Mail to:    Mail Stop 4004 
  Behavioral Pediatrics Division 
  The University of Kansas Medical Center 
  3903 Rainbow Boulevard 





Letter to Healthcare Provider 
[Healthcare Provider Name] 
 
The parent/guardian of one of your patients recently consented to participate in the 
Predictors of Initiating and Adhering to Medication for Attention-Deficit/Hyperactivity Disorder 
in Children study being conducted in partnership with the University of Oklahoma Health 
Sciences Center and the University of Kansas Medical Center.  I have included a copy of the 
authorization for the release of confidential information form signed by [parent/guardian name], 
[child’s name]’s [relationship to child].  During the informed consent process we explained to 
[parent/guardian name], that we would be contacting you to confirm the child’s ADHD diagnosis 
and current medications.  If you could either complete and return the information below, or send 
us this information in whatever format you currently have, we would greatly appreciate it.  
Please feel free to contact me with any questions you may have.  Thank you very much. 
 
The child listed below  ☐ does  ☐ does not receive care at our facility. 
 
Patient Name: ___________________________________________________ 
Date of Birth: ____________________________________________________ 
 
He/she  ☐ does  ☐ does not have a diagnosis of ADHD. 
 
Please list all of the child’s currently prescribed medications. 
 Medication Name Dosage Frequency 
   
   
   
   







Please do not hesitate to contact us with any questions or concerns. Thank you very much for 
your time and help.  
 
 
Catrina C. Litzenburg, M.A. 
OUHSC: Psychology Trainee 







Frontiers Research Participant Registry Phone Script 
“Hello. May I speak to the parent or guardian of [name]? My name is Catrina Litzenburg. I am 
contacting you because at some point you signed your child up for the Frontiers Research 
Participant Registry through a clinic at the University of Kansas Medical Center. This means that 
you agreed to be contacted if there are any studies for which your child might qualify. Our 
research team includes Drs. Stephen Lauer and Michael Rapoff from the Department of 
Pediatrics at KUMC. You are free to say “no” if you do not want your child to participate in the 
study. May I tell you about a study that we are conducting on initiating and adhering to 
medication for attention-deficit/hyperactivity disorder in children?” 
 
If no: “I appreciate your time. Were you aware of the registry before my calling? Had you been 
contacted for any other registry projects?” 
 
If yes: “By doing this study, researchers hope to learn more about what things are important 
when speaking to parents about deciding to give their child ADHD medication. If you decide to 
participate in this study, your participation will last approximately three months. Participation 
does not require any additional clinic visits and can take place entirely over the phone, Internet, 
and mail. The questionnaires and telephone interviews will take approximately 15 minutes each 
time to complete. You child’s medications will not change for the purpose of this study, but each 
prescription will be recorded at the pharmacy. Do you think you might be interested in 
participating?” 
 
If no: “I appreciate your time. Were you aware of the registry before my calling? Had you been 
contacted for any other registry projects?” 
 
If yes: “Do you mind if I ask you a few quick questions to see if you are eligible to participate in 
this study?  
 Is your child 6 to 12 years old? 
 Do they have a diagnosis of Pervasive Developmental Disorder or Mental  
Retardation? 
Has your child ever taken a medication to treat ADHD? 
Do you anticipate pursuing a medication to treat ADHD? Or are you currently 
considering medication options for ADHD? 
Does your child currently take any daily medications? If so, what are those?” 
 
“I will go ahead and mail you some additional information about the study. Is this your correct 
mailing address? … After you receive the information in the mail we will schedule a time to 
complete the informed consent process over the telephone. When is generally a convenient time 








The parent/guardian of one of your patients recently consented to participate in the 
Predictors of Initiating and Adhering to Medication for Attention-Deficit/Hyperactivity Disorder 
in Children study being conducted in partnership with the University of Oklahoma Health 
Sciences Center and the University of Kansas Medical Center.  I have included a copy of the 
authorization for the release of confidential information form signed by [parent/guardian name], 
[child’s name]’s [relationship to child].  During the informed consent process we explained to 
[parent/guardian name], that we would be contacting the pharmacy to obtain the child’s 
prescription history.  We need the name, number of pills dispensed, and date filled for each 
prescription for [child’s name], [Date of Birth], from [Date – 6 months prior] to present.  If you 
could either complete and return the information below, or send us this information in whatever 
format you currently have, we would greatly appreciate it.  Please feel free to contact me with 
any questions you may have.  Thank you very much for your time.  
 
The prescriptions included below have been filled for [Child’s name] in the past 6 months: 




     
     
     
     
 
   
 
Catrina C. Litzenburg, M.A. 
OUHSC: Psychology Trainee 








How are you related to the child who will be participating in this study?  
 Mother    Father 
 Grandparent    Other (please describe) ________________ 
What is your current marital status? 
 Single     Married    Separated 
 Divorced    Not married, live with partner 
Please describe the occupation of both parents. 
Mother:_________________________________________________________________ 
Father: _________________________________________________________________ 
Annual Household Income: 
 Less than $10,000   $10,001-$30,000 
 $30,001-$50,000   $50,001-$70,000 
 $70,001-$100,000   More than $100,001 
What type of health insurance does the child have?  
 Medicaid    Private 
Gender of the child:    Male    Female 
Child’s current grade in school: ______________________________________________ 
Please identify the child’s ethnicity. 
 Hispanic or Latino   Not Hispanic or Latino 
Please identify the child’s race.  Select all that apply. 
 American Indian or Alaska Native    Asian 
 Black or African American     White 
 Native Hawaiian or Other Pacific Islander 
What is the highest grade level completed by the child’s mother? 
 less than 7
th
 grade    junior high school 
 partial high school    high school graduate 
 some college or specialized training  college graduate 
 graduate/professional training 
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What is the highest grade level completed by the child’s father? 
 less than 7
th
 grade    junior high school 
 partial high school    high school graduate 
 some college or specialized training  college graduate 
 graduate/professional training 
Please list the name of the professional who diagnosed the child with ADHD. 
________________________________________________________________________ 
Is this person a psychologist or a medical doctor? 
 psychologist (Ph.D.)    medical doctor (M.D.) 
Please list any mental health diagnoses (other than ADHD) the child has. 
________________________________________________________________________ 
Is your child currently being seen by a mental health specialist to treat ADHD? 
 Yes     No 
What other ADHD treatments have you tried for your child? Please indicate if you are currently 
using the treatments. 
Past Current      Past Current 
  Behavioral parent training     Social skills training 
  Behavioral classroom management    Dietary changes 
  Anti-motion sickness medication    Play therapy 
  Individual child therapy     Cognitive therapy 
  Problem-solving communication training   Exercise 
  Optometric visual training     Sensory integration 
  Treatment for lead toxicity     Nutrition supplements 
  Interactive metronome training    Biofeedback 
  Candidas yeast therapy     Applied kinesiology 
  Treatment for thyroid dysfunction    Other  
(please describe):  ______________________________________________________________ 
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Do you have another child who has taken ADHD medication? 
 Yes     No 
How many other children (not including this one) do you have who have taken ADHD 
medication before?  _______________________________________________________ 
 
Do you have a family member, friend, or acquaintance that has a child who has taken ADHD 
medication?     Yes     No  
 
Did your child’s doctor say you could skip ADHD medication on the weekend?  
  Yes     No 
 
Do you intend to skip doses of ADHD medication on purpose? 
  Yes     No 
 




Please select the medication(s) the child is currently prescribed for ADHD.  Please select how 
often (frequency) the child is prescribed each medication.  
 
Trade Name (Generic Name) Frequency per day 
 
 Adderall (amphetamine)  Once  Twice  Three times 
 
 Adderall XR (amphetamine – 
extended release) 
 Once  Twice  Three times 
 
 Concerta (methylphenidate – long 
acting) 
 Once  Twice  Three times 
 
 Daytrana (methylphenidate patch)  Once  Twice  Three times 
 
 Desoxyn (methamphetamine 
hydrochloride) 
 Once  Twice  Three times 
 
 Dexedrine (dextroamphetamine)  Once  Twice  Three times 
 
 Dextrostat (dextroamphetamine)  Once  Twice  Three times 
 
 Focalin (dexmethylphenidate)  Once  Twice  Three times 
 
 Focalin XR (dexmethylphenidate – 
extended release) 
 Once  Twice  Three times 
 
 Intuniv (guanfacine)  Once  Twice  Three times 
 
 Metadate ER (methylphenidate – 
extended release) 
 Once  Twice  Three times 
 
 Metadate CD (methylphenidate – 
extended release) 
 Once  Twice  Three times 
 
 Methylin (methylphenidate – oral 
solution and chewable tablets) 
 Once  Twice  Three times 
 
 Ritalin (methylphenidate)  Once  Twice  Three times 
 
 Ritalin SR (methylphenidate – 
extended release) 
 Once  Twice  Three times 
 
 Ritalin LA (methylphenidate – long 
acting) 
 Once  Twice  Three times 
 
 Strattera (atomoxetine)  Once  Twice  Three times 
 
 Vyvanse (lisdexamfetamine 
dimesylate) 
 Once  Twice  Three times 
 






Protected Health Information Sheet 
Child’s date of birth: ____________________________________________________________ 
Mother’s date of birth: ___________________________________________________________ 
Father’s date of birth: ____________________________________________________________ 
Current mailing address: _________________________________________________________ 
______________________________________________________________________________ 
Current cell phone number: _______________________________________________________ 
Current home phone number: _____________________________________________________ 
Best time to reach you by phone: ___________________________________________________ 
What is the name of your child’s school? ____________________________________________ 
What is the name of your child’s school district? ______________________________________ 
Date of child’s ADHD diagnosis: __________________________________________________ 
Date your child began treatment for ADHD: __________________________________________ 
What is the name of the pharmacy where you have your child’s medications filled? 
______________________________________________________________________________ 
What is the address of the pharmacy where you have your child’s medications filled? 
______________________________________________________________________________
______________________________________________________________________________ 












Please mark the line below with a vertical stroke to show how much you agree with the 
statement.  A mark at the extreme left would show that you completely agree with the statement.  
A mark at the extreme right would show that you completely disagree with the statement.  A 
mark near the center would show that you neither disagree nor agree with the statement. 
 
 





  Agree        Disagree 
 
 
